KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
Kol CV for Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Påvirke statistikk
Kjør rapport
| Concept | World rank |
|---|---|
| fml patients | #1 |
| dscg symptoms | #1 |
| allergic postoperative | #1 |
| akc | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| sodium allergic | #1 |
| solution ocular | #1 |
| diseases tear | #1 |
| tacrolimus eye | #1 |
| fml administered | #1 |
| 12 patients akc | #1 |
| allerwatch higher | #1 |
| conjunctival cedar | #1 |
| postoperative conjunctivitis | #1 |
| nsaids systemic control | #1 |
| rapid ophthalmic | #1 |
| conjunctivitis conjunctival | #1 |
| il4 tranilast | #1 |
| cedrus conjunctivitis | #1 |
| efficacy bromfenac sodium | #1 |
| 01 tacrolimus eye | #1 |
| eyebon | #1 |
| dscg fml | #1 |
| antagonists child conjunctivitis | #1 |
| dscg 005 | #1 |
| eyewash solution | #1 |
| eye wash | #1 |
| include conjunctival | #1 |
| bromfenac sodium | #1 |
| fumarate dexamethasone | #1 |
| akc patients | #1 |
| eyewash solution bak | #1 |
| samples allergic conjunctivitis | #1 |
| allergic tranilast | #1 |
| bromfenac sodium bf | #1 |
| higher capilia | #1 |
| objective findings conclusions | #1 |
| atopic keratoconjunctivitis | #1 |
| severe binocular conjunctivitis | #1 |
| vkc conclusions | #1 |
| keratoconjunctivitis akc | #1 |
| allergic conjunctivitis | #1 |
| prostaglandin tears | #1 |
| cd3 cd4bearing cells | #1 |
| akc vkc | #1 |
| suspension treating | #1 |
| fluorometholone 002 | #1 |
| tears allergic patients | #1 |
| allerwatch diagnostic accuracy | #1 |
| talymus | #1 |
| eyewash | #1 |
| patients akc | #1 |
| adverse events scores | #1 |
| artificial tears positive | #1 |
| tranilast production | #1 |
| severe conjunctivitis eyes | #1 |
| pge2 human conjunctival | #1 |
| production tranilast | #1 |
| eyewash solutions | #1 |
| levocabastine artificial | #1 |
| allerwatch positivity rate | #1 |
| akc allergic | #1 |
| primary human conjunctival | #1 |
| suppressing pge2 production | #1 |
| conjunctivitis helper | #1 |
| bromobenzenes conjunctivitis | #1 |
| allergic corneal | #1 |
| subjective ocular symptoms | #1 |
| exacerbation vkc | #1 |
| tacrolimus ophthalmic | #1 |
| bf fml | #1 |
| tacrolimus ophthalmic solution | #1 |
| akc tear | #1 |
| dha il4 | #1 |
| conjunctivitis treated | #1 |
| bak epithelium | #1 |
| ocular allergic diseases | #1 |
| characterized conjunctival | #1 |
| allergic enzyme | #1 |
| ige allerwatch | #1 |
| commercial washing solution | #1 |
| itching levocabastine | #1 |
| initiating tacrolimus | #1 |
| commercial eyewash | #1 |
| severity objective signs | #1 |
| conjunctivitis japanese | #1 |
| tacrolimus ophthalmic suspension | #1 |
| capilia adeno eye | #1 |
| binocular conjunctivitis | #1 |
| clinical signs akc | #1 |
| capilia adeno | #1 |
| eotaxin1 production | #1 |
| positivity rate allerwatch | #1 |
| akc treatment | #1 |
| allergic conjunctivitis efficacy | #1 |
| 0001 allerwatch | #1 |
| 10 objective signs | #1 |
| 3 months signs | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| sodium ophthalmic solution | #1 |
| instillation symptoms | #1 |
| accuracy conjunctivitis | #1 |
| severe akc | #1 |
| bak epithelium disorders | #1 |
| production conjunctival fibroblasts | #1 |
| vkc april | #1 |
| ded anti | #1 |
| higher akc | #1 |
| inhibition eotaxin1 | #1 |
| production ketotifen fumarate | #1 |
| eye surface years | #1 |
| cox2 conjunctival | #1 |
| 01 ophthalmic solution | #1 |
| improvement combinedtreatment | #1 |
| tacrolimus eye drop | #1 |
| fourgraded severity | #1 |
| dscg bf | #1 |
| tranilast dexamethasone | #1 |
| initiation tacrolimus treatment | #1 |
| commercial eyewash solutions | #1 |
| eye fml | #1 |
| eye itching | #1 |
| corneal epithelium disorders | #1 |
| drops elicited | #1 |
| ketotifen fumarate dexamethasone | #1 |
| stat6results | #1 |
| compared fluorometholone | #1 |
| bromfenac sodium treatment | #1 |
| fml 002 | #1 |
| akc administration | #1 |
| allergenmediated conjunctivitis | #1 |
| instillation bromfenac | #1 |
| test capilia | #1 |
| hyperemia pain | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| tacrolimus tears | #1 |
| conclusions objective assessments | #1 |
| rate allerwatch | #1 |
| eye allerwatch | #1 |
| fml dscg | #1 |
| atopic keratoconjunctivitis akc | #1 |
| experience 01 | #1 |
| akc methods | #1 |
| patients atopic keratoconjunctivitis | #1 |
| adenovirus capilia | #1 |
| bf concomitantly | #1 |
| itchy sensation | #1 |
| radioimmunoassay il4 | #1 |
| tacrolimus eye drops | #1 |
| adult cedrus conjunctivitis | #1 |
| allerwatch tests | #1 |
| conjunctival fibroblasts | #1 |
| il4 tear | #1 |
| signs palpebral | #1 |
| pcr eotaxin1 | #1 |
| conjunctivitis concomitantly | #1 |
| conjunctivitis aims | #1 |
| patients allergic conjunctivitis | #1 |
| release inhibitor purpose | #1 |
| selective chemotactic effects | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| scleritis tacrolimus | #1 |
| drop levocabastine | #1 |
| allergic docosahexaenoic | #1 |
| iop akc | #1 |
| rsv conjunctival | #1 |
| allergic conjunctivitis drop | #1 |
| dha western blotting | #1 |
| akc vernal | #1 |
| scores hyperemia | #1 |
| cases severe conjunctivitis | #1 |
| incubated interleukin | #1 |
| keratocytes tnfα | #1 |
| therapy levocabastine | #1 |
| systemic control pain | #1 |
| patients severe conjunctivitis | #1 |
| keratoconjunctivitis vernal | #1 |
| conjunctivitis including | #1 |
| satisfaction suspensions | #1 |
| conjunctivitis enrolled | #1 |
| vkc cases | #1 |
| conjunctivitis seasonal | #1 |
| hundredandseventy eyes | #1 |
| akc compared | #1 |
| solution allergic | #1 |
| keratoconjunctivitis male | #1 |
| adeno eye | #1 |
| levocabastine artificial tears | #1 |
| action child conjunctivitis | #1 |
| immunocytochemical study rtpcr | #1 |
| tears allergic | #1 |
| patients capilia | #1 |
| vkc akc | #1 |
| sodium bf | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| selected fml | #1 |
| efficacy fml | #1 |
| tears conjunctival fibroblasts | #1 |
| child conjunctivitis | #1 |
| eyewash solutions bak | #1 |
| concomitant bf | #1 |
| epithelium disorders | #1 |
| allergens levocabastine | #1 |
| washing allergens | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| tacrolimus eye treatment | #1 |
| eyebon eye | #1 |
| keratoconjunctivitis background | #1 |
| epithelial pge2 | #1 |
| il4 causing | #1 |
| conjunctival fibroblasts production | #1 |
| tranilast eotaxin1 | #1 |
| adjustments epitheliopathy score | #2 |
| evaluate superiority | #2 |
| olopatadine cedar | #2 |
| csa akc | #2 |
| patients severe akc | #2 |
| akc patients correlation | #2 |
| sem575 | #2 |
| aided papillary | #2 |
| dryness scores | #2 |
| bromfenac ophthalmic solution | #2 |
| conjunctivitis adolescent | #2 |
| environmental studies prevalence | #2 |
| cornea grading | #2 |
| benzophenones bromobenzenes | #2 |
| diagnosis ensured | #2 |
| baseline papillae | #2 |
| noninferiority olopatadine | #2 |
| asthma heart diseases | #2 |
| drop concomitantly | #2 |
| corneal findings | #2 |
| 18 akc | #2 |
| simple papillary resection | #2 |
| neutrophils corneal damage | #2 |
| sodium bromfenac | #2 |
| lactoferrin 01 | #2 |
| air pollutants prevalence | #2 |
| cobblestonelike papillae | #2 |
| sem575 clinical | #2 |
| regrowth 7 eyes | #2 |
| steroids epitheliopathy | #2 |
| efficacy severe akc | #2 |
| japan akc | #2 |
| allergic diagnosis | #2 |
| total clinical signs | #2 |
| akc adult | #2 |
| skin elasticity patients | #2 |
| conjunctivitis 10 | #2 |
| akc levels | #2 |
| corneal damage height | #2 |
| treatment total signs | #2 |
| cac test | #2 |
| allergic conjunctivitis akc | #2 |
| keratoconjunctivitis corneal | #2 |
| akc 10 | #2 |
| severity corneal lesions | #2 |
| eyelid atopic dermatitis | #2 |
| folliculosis papillae | #2 |
| refractory allergic | #2 |
| corneal recurrences | #2 |
| elasticity eyelid | #2 |
| corneal ulcers patients | #2 |
| allergy accompanied | #2 |
| reported eotaxin | #2 |
| akc 10 eyes | #2 |
| post cataract surgery | #2 |
| epitheliopathy score | #2 |
| edema height | #2 |
| objective signs baseline | #2 |
| 001 brush | #2 |
| olopatadine visit | #2 |
| nonwash | #2 |
| improvement vital staining | #2 |
| patients shield ulcers | #2 |
| tear ige correlation | #2 |
| placebo noninferiority | #2 |
| allergic conjunctivitis levocabastine | #2 |
| administered elf bovine | #2 |
| adjuvant fluorometholone 95 | #2 |
| correlation eosinophils | #2 |
| akc treated | #2 |
| keratoconjunctivitis age | #2 |
| formation akc | #2 |
| conjunctiva bulbar | #2 |
| signs decreased | #2 |
| 2helper cell | #2 |
| adjuvant fluorometholone | #2 |
| akc adolescent | #2 |
| papillae severe | #2 |
| pge2 tears | #2 |
| immunoregulatory effects study | #2 |
| 95 adjuvant betamethasone | #2 |
| recurrence corneal lesions | #2 |
| severity corneal damage | #2 |
| corneal complications height | #2 |
| eyelid skin elasticity | #2 |
| patients tacrolimus eye | #2 |
| giant papillae formation | #2 |
| corneal epitheliopathy score | #2 |
| treatment atopic blepharitis | #2 |
| score topical | #2 |
| topical antiallergic agents | #2 |
| betamethasone glaucoma | #2 |
| eosinophils corneal damage | #2 |
| ulcer complain | #2 |
| conjunctivitis representative | #2 |
| steroid metaregression | #2 |
| akc aureus | #2 |
| superiority epinastine | #2 |
| vkc 5 | #2 |
| diabetic patients ono2235 | #2 |
| tacrolimus published data | #2 |
| pollutants prevalence | #2 |
| deqs tear | #2 |
| treated bromfenac | #2 |
| tacrolimus detection limit | #2 |
| tacrolimus topical | #2 |
| akc 1 | #2 |
| bromfenac sodium bromfenac | #2 |
| japan topical | #2 |
| patients corneal ulcers | #2 |
| endpoint itching scale | #2 |
| tears akc | #2 |
| atopic blepharitis | #2 |
| conjunctivitis condition | #2 |
| topical tacrolimus combination | #2 |
| correlation neutrophils | #2 |
| excision cobblestonelike papillae | #2 |
| tacrolimus 12 weeks | #2 |
| epinastine 15 minutes | #2 |
| largescale study protocol | #2 |
| eyes 824 | #2 |
| fluorescein conjunctival injection | #2 |
| oral aldose | #2 |
| formation palpebral | #2 |
| talymus akc | #2 |
| akc young adult | #2 |
| papillary excision | #2 |
| conjunctiva atopic | #2 |
| seasonal allergic conjunctivitis | #2 |
| cedrus conjunctiva | #2 |
| production specular | #2 |
| conjunctiva papillary | #2 |
| excision cobblestone | #2 |
| study designopen cohort | #2 |
| ensured proving | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| total signs symptoms | #2 |
| eyewash 005 | #2 |
| treatment tear | #2 |
| papillary formation | #2 |
| adjustments epitheliopathy | #2 |
| lower conjunctival sacs | #2 |
| diathesis subjective | #2 |
| scores tacrolimus | #2 |
| serum allergic parameters | #2 |
| papilla accompanied | #2 |
| lid skin | #2 |
| rhodanine rose | #2 |
| corneal epithelial signs | #2 |
| papillae limbus | #2 |
| resolution thermography | #2 |
| mmc aided | #2 |
| treatment shield ulcer | #2 |
| oral ari | #2 |
| corneal epitheliopathy | #2 |
| eyes betamethasone | #2 |
| swelling folliculosis | #2 |
| ophthalmic nsaid | #2 |
| conjunctival corneal cells | #2 |
| elasticity severity | #2 |
| mucin analyzed | #2 |
| suspension lactoferrin | #2 |
| concomitantly abovementioned | #2 |
| tacrolimus tonometry | #2 |
| oral ari administration | #2 |
| shield ulcers patients | #2 |
| allergic conjunctivitis ige | #2 |
| metaregression analysis glaucoma | #2 |
| lacrimation objective | #2 |
| bromfenac effective | #2 |
| female humans akc | #2 |
| muc16 immunohistochemistry | #2 |
| prevalence akc | #2 |
| tacrolimus iop | #2 |
| akc allergic diagnosis | #2 |
| drop steroid | #2 |
| epinastine superiority | #2 |
| correlation fluorescein | #2 |
| conjunctival injection edema | #2 |
| lessen steroid | #2 |
| solutions japan | #2 |
| papillae preventing | #2 |
| severe allergic conjunctivitis | #2 |
| conjunctival findings severity | #2 |
| neutrophils brush | #2 |
| complain foreign | #2 |
| methods thirtysix patients | #2 |
| aureussecreted enterotoxins | #2 |
| factor vkc | #2 |
| 062 tear | #2 |
| adjuvant betamethasone | #2 |
| blepharitis ceramides | #2 |
| detected akc | #2 |
| administered elf | #2 |
| cutometer sem575 | #2 |
| effects tacrolimus | #2 |
| papillae akc | #2 |
| test papillae | #2 |
| nonpreserved eyewash solution | #2 |
| tear film layer | #2 |
| limbal swelling | #2 |
| period rhodanine | #2 |
| ketotifen dexamethasone | #2 |
| conventional antiallergic drugs | #2 |
| akc 6 | #2 |
| ocular surface mucin | #2 |
| including akc | #2 |
| severity eyelid | #2 |
| premedication combined | #2 |
| conjunctivitis epitheliopathy | #2 |
| ari ocular | #2 |
| drops conjunctival | #2 |
| sem575 quantitatively | #2 |
| hyperemia lacrimation | #2 |
| cytodiagnosis dermatitis | #2 |
| unpaired ttest talymus | #2 |
| eyelid atopic | #2 |
| tacrolimus lessen | #2 |
| signs blood concentration | #2 |
| inflammatory child child | #2 |
| effects topical tacrolimus | #2 |
| sodium ophthalmic | #2 |
| epitheliopathy patients | #2 |
| eyelid elasticity | #2 |
| tacrolimus shield | #2 |
| based papillae | #2 |
| akc sac patients | #2 |
| severity corneal complications | #2 |
| mucous discharge severity | #2 |
| treatment ecp concentrations | #2 |
| suspension talymus | #2 |
| corneal damage patients | #2 |
| proliferative called | #2 |
| corneal temperature patients | #2 |
| ecp severity markers | #2 |
| brush cytology patients | #2 |
| regrowth papillae | #2 |
| epitheliopathy shield | #2 |
| decrease corneal temperature | #2 |
| drops refractory | #2 |
| score adjustments | #2 |
| solution epinastine | #2 |
| epitheliopathy steroids | #2 |
| elevation tacrolimus | #2 |
| disease antiallergic | #2 |
| oral ari ono2235 | #2 |
| epitheliopathy refractory | #2 |
| olopatadine ocular | #2 |
| tears thiazolidines | #2 |
| improvement corneal fluorescein | #2 |
| conjunctivitis purpose | #2 |
| dermatitis remission | #2 |
| patients shield | #2 |
| month eyewash | #2 |
| allergic endophthalmitis | #2 |
| corneal lesions regrowth | #2 |
| sac healthy | #2 |
| lesions allergic | #2 |
| bovine entericcoated lactoferrin | #2 |
| normal blinking patients | #2 |
| conclusions bromfenac | #2 |
| epitheliopathy corneal | #2 |
| conjunctivitis proliferative | #2 |
| vkc japan | #2 |
| papillae mucous discharge | #2 |
| accompanied subjective | #2 |
| corneal lesions | #2 |
| japan topical tacrolimus | #2 |
| atopic diagnostic techniques | #2 |
| ecp levels akc | #2 |
| recurrence corneal complications | #2 |
| conjunctival injection reduction | #2 |
| defined conjunctival | #2 |
| administration specular | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| edema corneal damage | #2 |
| tacrolimus detection | #2 |
| bovine placebo | #2 |
| extents corneal | #2 |
| giant papillary formation | #2 |
| plaques 791 | #2 |
| tarsal brush | #2 |
| selected bf | #2 |
| simple resection regrowth | #2 |
| scores papillary | #2 |
| height papillae | #2 |
| brush cytology samples | #2 |
| iop topical steroids | #2 |
| control subjects eyes | #2 |
| ceramide gel application | #2 |
| mmc 7 eyes | #2 |
| tacrolimus 1 month | #2 |
| drops hyperemia | #2 |
| 1 month tacrolimus | #2 |
| epinastine ophthalmic solution | #2 |
| representative subjective | #2 |
| conjunctivitis retrospective | #2 |
| ari corneal | #3 |
| corneal akc | #3 |
| vkc eyes | #3 |
| akc atopic dermatitis | #3 |
| tear periostin biomarker | #3 |
| flare metry | #3 |
| 01 ophthalmic | #3 |
| cell flare count | #3 |
| ophthalmic solution nsaid | #3 |
| fibronectin vkc | #3 |
| elisa histamine | #3 |
| dfna control | #3 |
| technique uncontrollable | #3 |
| pollen postoperative | #3 |
| tears adolescent | #3 |
| uncontrollable glaucoma | #3 |
| central corneal temperature | #3 |
| ecp severity | #3 |
| ulcers eyes | #3 |
| adedry eye | #3 |
| dry eye eye | #3 |
| vkc fibronectin | #3 |
| akc eyes | #3 |
| histamine conjunctival cells | #3 |
| hyperemia allergic | #3 |
| diclofenac epithelium | #3 |
| evaluate tear | #3 |
| 12 akc | #3 |
| dfna eye dfna | #3 |
| commercial washing | #3 |
| keratoconjunctivitis vkc | #3 |
| ulcers plaques | #3 |
| allergic cornea | #3 |
| vkc cell | #3 |
| cases vernal | #3 |
| titers ade | #3 |
| allergic corneal diseases | #3 |
| par2 benzamidines blotting | #3 |
| fibers lnfs | #3 |
| sligkv examined | #3 |
| cell metry | #3 |
| nbs subbasal | #3 |
| histamine specimens | #3 |
| benzamidine par2 | #3 |
| tear periostin patients | #3 |
| healing allergic | #3 |
| diabetic corneal disease | #3 |
| 3 sjögrens syndrome | #3 |
| permeability postoperatively | #3 |
| histamine cedar pollen | #3 |
| superficial cells conjunctiva | #3 |
| ulcer akc | #3 |
| conjunctivitis lymphocytes | #3 |
| nbs normal eyes | #3 |
| healing dramatic healing | #3 |
| conjunctival disease | #3 |
| giant papilla | #3 |
| dramatic healing | #3 |
| sdedry eye | #3 |
| vkc 5 eyes | #3 |
| insensible administration insensible | #3 |
| nuclei vkc | #3 |
| protein conjunctival fibroblasts | #3 |
| akc tear periostin | #3 |
| pilocarpine visante | #3 |
| 01 bromfenac | #3 |
| 5 eyes akc | #3 |
| drops treat | #3 |
| conjunctivitis pm25 | #3 |
| outpatient visits july | #3 |
| ebv ade | #3 |
| treatment oral pilocarpine | #3 |
| conjunctiva allergic | #3 |
| allergic patients conjunctivitis | #3 |
| signs remission | #3 |
| tryptase increases | #3 |
| 005 mmc | #3 |
| pm25 outpatient attendance | #3 |
| techniques tears | #3 |
| keratoconjunctivitis leupeptins | #3 |
| lnfs nbs | #3 |
| vkc long | #3 |
| 12 akc patients | #3 |
| lower muc5ac | #3 |
| diclofenac eye drops | #3 |
| allergic conjunctivitis aged | #3 |
| tear periostin comorbidities | #3 |
| vkc levels | #3 |
| cooling cataract | #3 |
| child conjunctiva | #3 |
| weekly average values | #3 |
| pm25 allergic | #3 |
| allerwatch | #3 |
| conjunctivitis benzamidines | #3 |
| cases vkc | #3 |
| antiallergic eye drop | #3 |
| improvement squamous metaplasia | #3 |
| papillae upper | #3 |
| alterations tear | #3 |
| cytology impression | #3 |
| 21 akc patients | #3 |
| formation vernal | #3 |
| oct graticule | #3 |
| laser cellflaremetry | #3 |
| diseases acds | #3 |
| samples correlate | #3 |
| histamine cedar | #3 |
| ulcer persistent | #3 |
| ophthalmic solution placebo | #3 |
| phenomena tacrolimus | #3 |
| study cutometer | #3 |
| 005 collagens | #3 |
| sde controls | #3 |
| akc serum periostin | #3 |
| mmc authors | #3 |
| existence par2 | #3 |
| insufficient tear supply | #3 |
| cholinergic treatment response | #3 |
| scored global | #3 |
| il1beta th2 | #3 |
| reaction conjunctiva | #3 |
| epithelium adverse | #3 |
| tmh measurement | #3 |
| tissue remodeling exacerbation | #3 |
| existence par2 mrna | #3 |
| 005 ophthalmic solution | #3 |
| thermography evaluate | #3 |
| treatment skin elasticity | #3 |
| 21 akc | #3 |
| hydrochloride 01 | #3 |
| akc biomarkers | #3 |
| postsurgical conjunctivitis | #3 |
| ssdry | #3 |
| differences dfna | #3 |
| conjunctivitis allergic | #3 |
| surgery dfna | #3 |
| eosinophils corneal | #3 |
| histamine superficial cells | #3 |
| periostin topical | #3 |
| treatment vernal | #3 |
| sensitivity tear | #3 |
| laser flarecellmetry | #3 |
| dfna eye | #3 |
| measurements schirmer | #3 |
| akc confocal microscopy | #3 |
| par2 cultured | #3 |
| induced inflammation lenses | #3 |
| akc alterations | #3 |
| fibronectin normal controls | #3 |
| fluorescein glycyrrhizic | #3 |
| akc persistent | #3 |
| operation eye | #3 |
| temperature evaluate | #3 |
| papillary resection | #3 |
| treatment strip meniscometry | #3 |
| patching patient | #3 |
| conjunctiva conjunctivitis | #3 |
| lacrimal punctal occlusion | #3 |
| higher muc1 eyes | #3 |
| aureus akc patients | #3 |
| eyes control subjects | #3 |
| tear il13 | #3 |
| icecold eye mask | #3 |
| eyes vkc | #3 |
| cultured tryptase | #3 |
| july pm25 | #3 |
| superior limbic portion | #3 |
| epinastine placebo | #3 |
| immunosuppressive eye | #3 |
| muc1 brush cytology | #3 |
| papillae morphometric | #3 |
| inflammation mmc | #3 |
| conjunctivitis negative | #3 |
| vkc exacerbation | #3 |
| 13 eyes 69 | #3 |
| vkc papillae | #3 |
| traumatic swelling | #3 |
| technique 2 eyes | #3 |
| oct tmh | #3 |
| rtpcr par2 | #3 |
| patients pilocarpine tablets | #3 |
| vkc relevant factor | #3 |
| eye cooling | #3 |
| decline corneal | #3 |
| association outpatient attendance | #3 |
| akc periostin | #3 |
| tryptase conjunctiva | #3 |
| relevant factor exacerbation | #3 |
| dibenzoxepins female | #3 |
| eye washing | #3 |
| pretreatment docosahexaenoic acid | #3 |
| local tear deficiency | #3 |
| portable recordable | #3 |
| underwent periodic | #3 |
| eyes allergic | #3 |
| allergic corneal ulcer | #3 |
| severe allergic patients | #3 |
| 111 177 | #3 |
| increased comfort | #3 |
| tears treatment | #3 |
| tear periostin | #3 |
| patching case | #3 |
| ocular surface diabetes | #3 |
| metry dfna | #3 |
| antieaigg | #3 |
| aged biological dressings | #3 |
| corneal complications1 | #3 |
| macroerosions | #3 |
| prospectively diclofenac | #3 |
| healed amniotic | #3 |
| akc confocal | #3 |
| fluorescein scale | #3 |
| rose bengal akc | #3 |
| periostin akc | #3 |
| lamp device | #3 |
| severe allergy patients | #3 |
| allergic postsurgical | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| nonpreserved artificial tears | #3 |
| strip meniscometry testing | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| dfna diclofenac epithelium | #3 |
| cells brush cytology | #3 |
| mmcaided papillary resection | #3 |
| 22 eyes 100 | #3 |
| antibody titers ade | #3 |
| prophylaxis conjunctival | #3 |
| interleukin4 tacrolimus | #3 |
| conjunctival corneal | #3 |
| infrared radiation thermography | #3 |
| techniques conjunctivitis | #3 |
| erosions refractory | #3 |
| topical cyclosporine 01 | #3 |
| outpatient visits august | #3 |
| papillary regrowth | #3 |
| efficacy bromfenac | #3 |
| drop selected | #3 |
| akc higher | #3 |
| akc higher muc1 | #3 |
| membrane uncontrollable | #3 |
| corneal epithelial structure | #3 |
| formation vkc | #3 |
| 5ac mrna | #3 |
| vkc differences | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| akc rose bengal | #3 |
| pollen august | #3 |
| production conjunctival | #3 |
| scale tmh | #3 |
| solutions prospective | #3 |
| mmc excision | #3 |
| outpatient attendance july | #3 |
| underwent staining | #3 |
| superior keratoconjunctiva | #3 |
| akc comorbidities | #3 |
| patients tmh measurements | #3 |
| glaucoma amniotic | #3 |
| proving type | #3 |
| 1 month initiation | #3 |
| aged elisa | #3 |
| cornea atopic | #3 |
| injections keratoconjunctivitis | #3 |
| vivo corneal akc | #3 |
| il1beta th2 cytokines | #3 |
| periostin comorbidities | #3 |
| akc dyes humans | #3 |
| vkc sac | #3 |
| 5ac brush | #3 |
| eyes akc | #3 |
| conjunctival fibroblasts tryptase | #3 |
| corneal ulceration role | #3 |
| interleukin4 histamine | #3 |
| dscg administration | #3 |
| normal controls collagens | #3 |
| insufficient tear | #3 |
| autumnal pollen | #3 |
| healthy individuals rtpcr | #4 |
| sio2 20 | #4 |
| formation conjunctivitis | #4 |
| tears patients | #4 |
| temperature corneal | #4 |
| exponential equation inclination | #4 |
| bromfenac eye drops | #4 |
| samples histocytological | #4 |
| 10 seconds temperature | #4 |
| treatment vmr | #4 |
| sensitization asian dust | #4 |
| akc chemotaxis | #4 |
| metaplasia reduction | #4 |
| akc pgd2dependent migration | #4 |
| simple resection | #4 |
| sac control eyes | #4 |
| rsv conjunctiva | #4 |
| noninfectious necrotizing | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| vkc messenger reverse | #4 |
| akc immunologic receptors | #4 |
| thermometer 20 | #4 |
| excision papillary | #4 |
| tear function patients | #4 |
| epithelial disease patients | #4 |
| portable slit | #4 |
| include ocular | #4 |
| controls brush cytology | #4 |
| eyes corneal ulcers | #4 |
| 33 chemokines | #4 |
| patients severe vkc | #4 |
| epithelial muc | #4 |
| surface conjunctival | #4 |
| eosinophils receptor crth2 | #4 |
| adolescent betamethasone | #4 |
| photophobia diagnosis | #4 |
| pcr epithelial | #4 |
| il4 tears | #4 |
| insignificant epithelial disease | #4 |
| eye wash solution | #4 |
| rsv conjunctival epithelium | #4 |
| highrisk glaucoma patients | #4 |
| compared vkc | #4 |
| eyes ulcers | #4 |
| ded 1 | #4 |
| corneal ulcers eyes | #4 |
| 3004 respondents | #4 |
| conjunctival proliferative | #4 |
| muc5ac mrna expression | #4 |
| eyes insignificant | #4 |
| inflammation akc | #4 |
| folliculosis | #4 |
| eyes akc patients | #4 |
| vkc 4 | #4 |
| pgd2 normal volunteers | #4 |
| fibroblasts primary sources | #4 |
| untreated asian dust | #4 |
| epithelial cells rsv | #4 |
| tacrolimus conclusions | #4 |
| drop artificial tears | #4 |
| patients epithelial disease | #4 |
| corneal temperature eye | #4 |
| level conjunctiva | #4 |
| 0001 brush | #4 |
| special brush | #4 |
| acds conventional | #4 |
| grade dry eye | #4 |
| corneal sensitivity measurement | #4 |
| thermography anterior | #4 |
| individuals pgd2 | #4 |
| thinoptx | #4 |
| cultured conjunctival | #4 |
| tablets tears | #4 |
| tryptase dose | #4 |
| akc crth2 | #4 |
| allergic conjunctival disease | #4 |
| 4 chemokines stimulation | #4 |
| patient atopic keratoconjunctivitis | #4 |
| conjunctivitis vkc | #4 |
| metaregression analysis effects | #4 |
| allergic conjunctival | #4 |
| giemsas staining | #4 |
| months papillary | #4 |
| diseases portable | #4 |
| allergic patients elisa | #4 |
| goblet cell muc5ac | #4 |
| muc5ac alterations | #4 |
| atopic ocular | #4 |
| implantation thinoptx | #4 |
| studied corneal | #4 |
| dscg day | #4 |
| deqs scores | #4 |
| 2 4 alterations | #4 |
| 2010 allergic | #4 |
| vkc normal controls | #4 |
| greater 3 grade | #4 |
| crth2 akc | #4 |
| akc healthy | #4 |
| vkc male receptors | #4 |
| pathogenesis noninfectious | #4 |
| staining muc | #4 |
| clinical conjunctival | #4 |
| surface muc5ac | #4 |
| thinoptx lens | #4 |
| cases sufficient examination | #4 |
| solutions piperidines | #4 |
| eotaxin1 rantes | #4 |
| microscope evaluating | #4 |
| mucin mucins tears | #4 |
| conjunctivitis methods | #4 |
| membrane patching | #4 |
| hypersensitivity mucin | #4 |
| insignificant epithelial | #4 |
| tear function test | #4 |
| interleukin2 tears | #4 |
| corneal sensitivity measurements | #4 |
| epithelial disease eyes | #4 |
| staining ocular | #4 |
| tears pathogenesis | #4 |
| thinoptx acrysof | #4 |
| akc rtpcr | #4 |
| july pollen | #4 |
| muc16 goblet | #4 |
| pgd2dependent migration | #4 |
| papillae giant | #4 |
| acuity akc | #4 |
| muc1 2 | #4 |
| corneal temperature blink | #4 |
| fungi epidemiologic studies | #4 |
| infected conjunctival | #4 |
| ari ono2235 | #4 |
| rsv allergic reaction | #4 |
| chemokine genes fibroblasts | #4 |
| tomography tear | #4 |
| interferometry controls | #4 |
| greater concentrations tears | #4 |
| cytometry mild | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| lesions regrowth | #4 |
| atopic vernal | #4 |
| ophthalmologists eye drops | #4 |
| bromfenac ophthalmic | #4 |
| wilcoxon signed test | #4 |
| samples allergic | #4 |
| lower tear function | #4 |
| cells lnfs | #4 |
| keratoconjunctivitis purpose | #4 |
| bengal sensation | #4 |
| cytometry mild cases | #4 |
| rose bengal scores | #4 |
| conjunctiva density | #4 |
| mucins 1 | #4 |
| controls interferometry | #4 |
| conjunctivitis ige | #4 |
| akc crth2 expression | #4 |
| interferometry 2 | #4 |
| erosion shield | #4 |
| limbal grafts | #4 |
| allergic conjunctival diseases | #4 |
| papillae normal | #4 |
| defensins greater | #4 |
| atopic ocular allergies | #4 |
| corneal ulcers muc5ac | #4 |
| steroids fluorometholone | #4 |
| staining muc16 | #4 |
| rejection limbal | #4 |
| allergic fibroblasts | #4 |
| chemotaxis conjunctiva | #4 |
| treatment vmr values | #4 |
| disease akc | #4 |
| placebo ophthalmic | #4 |
| sterilized asian | #4 |
| moisture checker | #4 |
| thinoptx intraocular | #4 |
| allergies blinding | #4 |
| crth2 peripheral | #4 |
| conventional portable | #4 |
| eosinophil toxic activity | #4 |
| blinding purpose | #4 |
| recordable slit | #4 |
| weeks vital | #4 |
| ocular allergic disease | #4 |
| eyes video | #4 |
| muc16 muc5ac alterations | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| immunologic receptors akc | #4 |
| completely severe | #4 |
| hydrochloride ophthalmic | #4 |
| ulcers control subjects | #4 |
| trantas | #4 |
| correlation outpatient | #4 |
| corneal safety | #4 |
| 020 013 | #4 |
| eye sjögrens syndrome | #4 |
| ocular surface epithelial | #4 |
| diameter allergen | #4 |
| epithelial muc16 | #4 |
| akcaffected patients | #4 |
| male ophthalmic | #4 |
| p0001 impression | #4 |
| genes conjunctival | #4 |
| defensins conjunctivitis | #4 |
| 061 028 degree | #4 |
| controls interferometry grade | #4 |
| ulcers mucin | #4 |
| akc sac | #4 |
| persistent 6 | #4 |
| assay pgd2 | #4 |
| vmr 3 months | #4 |
| muc5ac brush cytology | #4 |
| eyes thinoptx | #4 |
| p0001 brush | #4 |
| scores conjunctival | #4 |
| histamine h1 antagonist | #4 |
| conjunctiva differences | #4 |
| specimens underwent | #4 |
| cytology goblet | #4 |
| dust wheal | #4 |
| patients topical cyclosporine | #4 |
| patient eyes fluorescein | #4 |
| ige conjunctival | #4 |
| ophthalmologists evaluated | #4 |
| lower tear clearance | #4 |
| tear temperature | #4 |
| asian dust extract | #4 |
| severe vkc patients | #4 |
| mucins tears mucin | #4 |
| levocabastine h1 | #4 |
| eye operation | #4 |
| tnfalpha30ng | #4 |
| keratoconjunctivitis lacrimal | #4 |
| interferometry grade | #4 |
| levocabastine ophthalmic | #4 |
| topical 01 tacrolimus | #4 |
| conjunctivitis levels | #4 |
| ulcers atopic | #4 |
| alterations atopic | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| implantation rollable | #4 |
| aged rose | #4 |
| fva treatment | #4 |
| 18 akc patients | #4 |
| muc5ac brush | #4 |
| cornea grading scale | #4 |
| acds ophthalmologists | #4 |
| par2 mrna protein | #4 |
| sac grade | #4 |
| steroids iop | #4 |
| subjects muc5ac | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| proteinchip array elisa | #4 |
| atopic dermatitis remission | #4 |
| topical oral steroids | #4 |
| akc healthy individuals | #4 |
| sensation tears | #4 |
| allergic conjunctivitis rsv | #4 |
| samples immunocytochemical | #4 |
| conjunctival papillary | #4 |
| tears 10 patients | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| pgd2dependent migration eosinophils | #4 |
| allergic epidemiologic studies | #4 |
| cell muc5ac | #4 |
| epithelial pge2 production | #4 |
| interferometry lipids | #4 |
| allergic cytological | #4 |
| epinastine hydrochloride | #4 |
| primary sources chemokines | #4 |
| performed tears | #4 |
| underwent corneal | #4 |
| eyes sac | #4 |
| stimulation chemokine expression | #4 |
| eyes epithelial disease | #4 |
| severe ocular allergies | #4 |
| sterilized asian dust | #4 |
| 34 15 seconds | #4 |
| oedema papillary | #4 |
| meniscus punctal | #5 |
| scores expressibility | #5 |
| thinoptx iol | #5 |
| crth2 prostaglandin receptors | #5 |
| prostaglandin chemotaxis | #5 |
| controls ebv | #5 |
| damaged eosinophil | #5 |
| ocular allergic | #5 |
| solution olopatadine | #5 |
| vkc atopic | #5 |
| 17 mgd patients | #5 |
| lipid oxidation hel | #5 |
| treatment epinastine | #5 |
| conjunctivitis pollen | #5 |
| eosinophil adherence fibroblasts | #5 |
| schirmer1 test groups | #5 |
| histamine superficial | #5 |
| lesion corneal | #5 |
| impression brush | #5 |
| month tear | #5 |
| tears received | #5 |
| hel akc | #5 |
| akc normal subjects | #5 |
| conjunctival inflammatory status | #5 |
| asthenopia dry | #5 |
| local tear | #5 |
| thiazolidines administration | #5 |
| study epinastine | #5 |
| crth2 eosinophils | #5 |
| mitomycin excision | #5 |
| fibroblasts eosinophil adherence | #5 |
| keratoconjunctivitis giant | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| controls inflammatory cells | #5 |
| disease conjunctivitis | #5 |
| females akc | #5 |
| measurements strip | #5 |
| severe stevensjohnson syndrome | #5 |
| hne ihc | #5 |
| 0001 strip | #5 |
| damage impression | #5 |
| case corneal ulcer | #5 |
| stainings tear | #5 |
| layer mgd | #5 |
| akc acinar | #5 |
| 3 cases followup | #5 |
| conjunctiva dermatitis | #5 |
| stained conjunctival | #5 |
| akc laser | #5 |
| dryeye symptoms | #5 |
| stimulated conjunctival | #5 |
| staining administration | #5 |
| hel cytokines | #5 |
| schiff immunohistochemical | #5 |
| akc disease | #5 |
| ophthalmic test | #5 |
| antifungal mcfg | #5 |
| diseases required | #5 |
| inflammation mitomycin | #5 |
| severe conjunctivitis | #5 |
| 310±165 years | #5 |
| lower atopic | #5 |
| ulcers controls | #5 |
| warmer improved | #5 |
| eosinophils activated fibroblasts | #5 |
| hel ihc | #5 |
| accompanying allergic | #5 |
| ulcer dermatitis | #5 |
| accompanied varying | #5 |
| 376±56 years | #5 |
| eye circulating | #5 |
| conjunctivitis prostaglandin | #5 |
| treatment dryeye symptoms | #5 |
| adolescent conjunctivitis | #5 |
| 7 conjunctival | #5 |
| visits july | #5 |
| conjunctiva mmc | #5 |
| equipment dry | #5 |
| labeling surface akc | #5 |
| allergic female | #5 |
| disposable eyelid | #5 |
| inflammatory cells hel | #5 |
| cornea cytodiagnosis | #5 |
| cells vkc | #5 |
| adhered corneal | #5 |
| pgd2 normal | #5 |
| samples akc | #5 |
| signs akc | #5 |
| staining muc5ac | #5 |
| bengal suture | #5 |
| months amniotic | #5 |
| array chemotaxis | #5 |
| eye warmer treatment | #5 |
| conjunctival lipid | #5 |
| 01 mcfg | #5 |
| akc ecp | #5 |
| situ nickend regulation | #5 |
| keratoconjunctivitis objective | #5 |
| 005 schirmer1 | #5 |
| intraoperative mitomycin excision | #5 |
| eosinophils immunologic receptors | #5 |
| upper palpebral | #5 |
| allergic keratopathy | #5 |
| conjunctival allergen | #5 |
| cytokinestimulation | #5 |
| scans akc | #5 |
| impression cytology samples | #5 |
| pretreatment dha | #5 |
| 20 akc patients | #5 |
| allergic conjunctivitis patients | #5 |
| akc patients study | #5 |
| simple papillary | #5 |
| tnfα costimulation | #5 |
| regulation allergic cornea | #5 |
| topical cyclosporine therapy | #5 |
| oct lower | #5 |
| severity akc | #5 |
| solutions pollen | #5 |
| human conjunctival fibroblasts | #5 |
| alpha allergic | #5 |
| status confocal | #5 |
| treatment tacrolimus ointment | #5 |
| ihc conjunctival inflammation | #5 |
| age 9 ± | #5 |
| vcam1 fibroblasts | #5 |
| allergic cyclosporine | #5 |
| postsurgical inflammation | #5 |
| anterior fluorometry | #5 |
| 329±57 years | #5 |
| endophthalmitis eosinophils | #5 |
| diclofenac eye | #5 |
| anterior scleritis patients | #5 |
| punctal occlusion oct | #5 |
| trantas dots | #5 |
| conjunctival confocal microscopy | #5 |
| allergic drug therapy | #5 |
| fibroblasts fibroblast damage | #5 |
| corneal fibroblasts icam1 | #5 |
| ocular surface disorder | #5 |
| dryeye symptoms treatment | #5 |
| cornea explain | #5 |
| wilcoxonmatched pair test | #5 |
| pm25 outpatient | #5 |
| bromobenzenes cornea | #5 |
| mcfg eye | #5 |
| eosinophil adhesion fibroblasts | #5 |
| il4 histamine | #5 |
| 15 minutes dose | #5 |
| worse akc | #5 |
| warmer applied | #5 |
| akc hel | #5 |
| injection conjunctival | #5 |
| visits august | #5 |
| treatment shield | #5 |
| temperature blink | #5 |
| ophthalmic suspension | #5 |
| cases tests | #5 |
| 20 sio2 | #5 |
| vkc iop | #5 |
| supernatants conjunctival | #5 |
| younger age effects | #5 |
| ocular anesthesia | #5 |
| 5 females akc | #5 |
| eye warmer | #5 |
| alterations ocular | #5 |
| disposable eyelidwarming device | #5 |
| corneal involvement | #5 |
| conventional steroid treatment | #5 |
| eyes atopic | #6 |
| tranilast inhibition | #6 |
| female fluorometholone | #6 |
| dressings female | #6 |
| corneal fibroblasts pathogenesis | #6 |
| 4 muc | #6 |
| dfna | #6 |
| topical levocabastine | #6 |
| signs scored | #6 |
| inflammatory cell densities | #6 |
| concomitant eye | #6 |
| papillae mucous | #6 |
| cys ocular | #6 |
| topical cys | #6 |
| agents interferometry | #6 |
| tears acinar | #6 |
| ecp markers | #6 |
| allergic diathesis | #6 |
| tear stability values | #6 |
| topical cys treatment | #6 |
| tbut vital | #6 |
| solution commercial | #6 |
| rtpcr epithelial cells | #6 |
| differences tear | #6 |
| severe ocular inflammation | #6 |
| samples underwent | #6 |
| evaporation vital | #6 |
| hyperemia imidazoles | #6 |
| levels air pollutants | #6 |
| ocular fatigue | #6 |
| atopic eyelids | #6 |
| bengal vital stainings | #6 |
| strip meniscometry scores | #6 |
| testing tear | #6 |
| dust asian | #6 |
| regulation benzamidines | #6 |
| itching conjunctival | #6 |
| tear ecp | #6 |
| hyperemia swelling | #6 |
| diseases periostin | #6 |
| il4 il2r | #6 |
| pathogenesis ocular | #6 |
| akc refractory | #6 |
| allergens cedrus | #6 |
| corneal temperature | #6 |
| dermatitis scored | #6 |
| tear meniscus patients | #6 |
| schirmer1 test values | #6 |
| cgvhd improvements | #6 |
| rate tbut | #6 |
| instability conjunctival | #6 |
| eosinophils crth2 | #6 |
| fva landolt | #6 |
| conjunctival brush cytology | #6 |
| fibroblasts conjunctival | #6 |
| intolerable irritation | #6 |
| eosinophil recruiting chemokines | #6 |
| corneal damage | #6 |
| treatment postoperative inflammation | #6 |
| upper tarsal conjunctiva | #6 |
| tears xerophthalmia | #6 |
| elasticity cutometer | #6 |
| obstructive mgd patients | #6 |
| ocular surface findings | #6 |
| sac vkc | #6 |
| elevation refractory | #6 |
| conjunctival diseases | #6 |
| tryptase proliferation | #6 |
| allergic conjunctivitis cac | #6 |
| noninvasive suction device | #6 |
| defect penetrating | #6 |
| edema severity | #6 |
| symptoms vkc | #6 |
| severe stevens | #6 |
| tacrolimus chronic | #6 |
| chloride eye | #6 |
| 4 9 genes | #6 |
| patients seldi | #6 |
| 20 pbs | #6 |
| challenge cac | #6 |
| examinations tear | #6 |
| sde ade | #6 |
| extract sterilized | #6 |
| specimens akc | #6 |
| levocabastine effective | #6 |
| scores goblet | #6 |
| ade sde | #6 |
| cyclosporine 01 | #6 |
| twicedaily instillation | #6 |
| severe vkc | #6 |
| defect ped | #6 |
| eye evaluated | #6 |
| density conjunctival | #6 |
| july correlation | #6 |
| treatment tacrolimus | #6 |
| ointment blood | #6 |
| remodeling vkc | #6 |
| rose bengal dyes | #6 |
| severe vernal | #6 |
| betamethasone oral | #6 |
| syndrome tablets | #6 |
| functions topical | #6 |
| conjunctival confocal | #6 |
| akc vernal keratoconjunctivitis | #6 |
| controlling eyelid | #6 |
| coated elf | #6 |
| patients visante | #6 |
| tear eosinophil | #6 |
| pcr muc5ac | #6 |
| conjunctivitis sac | #6 |
| induced tear | #6 |
| antiallergic eye | #6 |
| grading tear | #6 |
| oxidation hel | #6 |
| findings dry eye | #6 |
| fluorometholone follow | #6 |
| amniotic membrane patching | #7 |
| corneal lesion | #7 |
| nonparametric tears | #7 |
| nerves tear | #7 |
| tear supply | #7 |
| tears th2 | #7 |
| inhibitor ono2235 | #7 |
| papillae formation | #7 |
| solution bf | #7 |
| allergic eyelid | #7 |
| ulcers revealed | #7 |
| attendance allergic | #7 |
| status atopic | #7 |
| steroidal benzophenones | #7 |
| increases proliferative | #7 |
| western blotting nfκb | #7 |
| mucins periodic | #7 |
| conjunctivitis dry | #7 |
| tmh measurements | #7 |
| allergic dna | #7 |
| evaluation eyelid | #7 |
| revealed eosinophils | #7 |
| incidence meibomian | #7 |
| sources chemokines | #7 |
| ocular inflammatory disorder | #7 |
| conclusion mmc | #7 |
| necrotizing anterior | #7 |
| concentrations conjunctival | #7 |
| injection oedema | #7 |
| tears alpha | #7 |
| sensitization asian | #7 |
| gpc vkc | #7 |
| mmc 005 | #7 |
| sensation symptom | #7 |
| conjunctiva brush | #7 |
| eyelid surface | #7 |
| development allergic conjunctivitis | #7 |
| administration fluorescein | #7 |
| examination tear | #7 |
| meniscometry testing | #7 |
| conjunctivitis risk | #7 |
| 4 tear | #7 |
| pge2 cox2 levels | #7 |
| crth2 normal | #7 |
| eczema frequently | #7 |
| neutrophils corneal | #7 |
| cytology differ | #7 |
| age 325 years | #7 |
| rose bengal fluorescein | #7 |
| surgery cooling | #7 |
| procedures radioimmunoassay | #7 |
| thought pathogenesis | #7 |
| conjunctival brush | #7 |
| silicone plugs | #7 |
| tacrolimus topical steroids | #7 |
| conjunctival inflammatory | #7 |
| mmc observed | #7 |
| accommodating intraocular lens | #7 |
| adult blepharitis | #7 |
| conjunctival complications | #7 |
| cases preventing | #7 |
| vkc gpc | #7 |
| key prostaglandin | #7 |
| hrtii rcm | #7 |
| 10 clinical signs | #7 |
| patients comfort level | #7 |
| mucins tears | #7 |
| normal blinking | #7 |
| pathogenesis subsequent | #7 |
| prostaglandin atopic | #7 |
| suspension 01 | #7 |
| collected brush | #7 |
| improvements symptom scores | #7 |
| ulceration healthy | #7 |
| eyes ophthalmologists | #7 |
| ulcer corneal | #7 |
| superiority placebo | #7 |
| tacrolimustreated eyes | #7 |
| pgd2 dependent | #7 |
| severe persistent cases | #7 |
| 0001 impression | #7 |
| hyperemia adverse | #7 |
| chemotaxis eosinophils | #7 |
| alpha tears | #7 |
| blinking body | #8 |
| induced intraocular | #8 |
| blinking desiccation | #8 |
| alterations cornea | #8 |
| occlusion lacrimal | #8 |
| graticule scale | #8 |
| infrared radiation thermometry | #8 |
| corneal fibroblasts tnfalpha | #8 |
| akc patients controls | #8 |
| corneal epithelial lesions | #8 |
| meniscometry tear | #8 |
| allergic dibenzazepines | #8 |
| chemotaxis pgd2 | #8 |
| correlation vital | #8 |
| conjunctivitis eyes | #8 |
| ihc hel | #8 |
| values slit | #8 |
| controls seldi | #8 |
| fluorescein rose bengal | #8 |
| techniques keratoconjunctivitis | #8 |
| rollable intraocular | #8 |
| akc subjects | #8 |
| classified allergic | #8 |
| age 170 ± | #8 |
| expressions thought | #8 |
| alterations allergic | #8 |
| flare counts | #8 |
| corneal scores | #8 |
| corneal ulcer | #8 |
| par2 mast cells | #8 |
| asia cats | #8 |
| controls brush | #8 |
| diameter acinar | #8 |
| keratocytes cytokines | #8 |
| mitomycin post | #8 |
| microscopy conjunctival | #8 |
| superficial cells groups | #8 |
| underwent tear | #8 |
| stainings schirmer | #8 |
| betamethasone calcineurin | #8 |
| noninfectious corneal | #8 |
| teros | #8 |
| conjunctival findings | #8 |
| staining hel | #8 |
| stained hel | #8 |
| patients corneal | #8 |
| meniscometry scores | #8 |
| tnfalpha eosinophils | #8 |
| patients vkc | #8 |
| definite dry eye | #8 |
| trabeculectomy amniotic | #8 |
| teros values | #8 |
| pollen odds | #8 |
| radiation thermography | #8 |
| fva measurements | #8 |
| ccl5 conjunctiva | #8 |
| pathogenesis test | #8 |
| scores teros | #8 |
| oedema scores | #8 |
| hoc analysis study | #8 |
| palpebral bulbar | #8 |
| eye redness | #8 |
| limbalbased conjunctival flap | #8 |
| il4 enzyme | #8 |
| conjunctival sensation | #8 |
| brush cytology | #8 |
| 006 degree | #8 |
| itching hyperemia | #8 |
| ulcers detected | #8 |
| 4 chemokines | #8 |
| blink patients | #8 |
| surface teros | #8 |
| sac akc | #8 |
| transient burning sensation | #8 |
| elisa tears | #9 |
| ono2235 | #9 |
| sio2 pbs | #9 |
| histocytological study | #9 |
| vital stainings | #9 |
| conjunctivitis cases | #9 |
| 0001 schirmer | #9 |
| design eyelid | #9 |
| clinical ocular findings | #9 |
| fluorescein rose | #9 |
| eye grade | #9 |
| injection edema | #9 |
| vital staining scores | #9 |
| prospective study tacrolimus | #9 |
| pathogen allergic | #9 |
| implantation 1cu | #9 |
| cobblestone papillae | #9 |
| prevalence vkc | #9 |
| severity corneal | #9 |
| shield ulcers | #9 |
| pretreatment docosahexaenoic | #9 |
| tacrolimus 95 | #9 |
| subjective ocular | #9 |
| hyperemia iop | #9 |
| fatigue dry | #9 |
| symptoms allergic conjunctivitis | #9 |
| cases conjunctivitis | #9 |
| stress staining | #9 |
| hel 4 | #9 |
| concentration tears | #9 |
| patients tacrolimus treatment | #9 |
| wash solution | #9 |
| pollution conjunctivitis | #9 |
| genes cxc | #9 |
| sufficient examination | #9 |
| specular microscopic evaluation | #9 |
| sensitivity confocal | #9 |
| diagnosis conjunctivitis | #9 |
| mmc recurrence | #9 |
| tnfalpha fibroblasts | #9 |
| tears thermography | #9 |
| tacrolimus treating | #9 |
| operatedon eye | #9 |
| blood level tacrolimus | #9 |
| observed obstructive | #9 |
| cys eye | #9 |
| smart eye | #9 |
| crth2 expression eosinophils | #9 |
| glaucoma younger age | #9 |
| diseases conjunctivitis | #9 |
| untreated asian | #9 |
| tear level | #9 |
| excision intraoperative | #9 |
| received preserved | #9 |
| reductase cataract | #9 |
| differ allergic | #9 |
| foreign body sensation | #9 |
| measurements vital | #9 |
| level pollutants | #9 |
| sensitivity conjunctival | #9 |
| supply superior | #9 |
| conjunctival fibroblast | #9 |
| acid goblet | #9 |
| prevalence weather | #9 |
| pilocarpine tablets | #9 |
| superior limbic | #9 |
| inflammation steroidal | #9 |
| eye normal subjects | #9 |
| ophthalmic adolescent | #10 |
| conjunctivitis histamine | #10 |
| muc16 muc5ac | #10 |
| assessed conjunctival | #10 |
| diagnosis dry eye | #10 |
| subbasal stromal | #10 |
| lacrimal puncta | #10 |
| resection regrowth | #10 |
| cornea eosinophils | #10 |
| tear cytology | #10 |
| conjunctivitis atopic | #10 |
| iop hyperemia | #10 |
| eye surface | #10 |
| levels tears | #10 |
| icam1 tnfalpha | #10 |
| drugs conjunctival | #10 |
| tears 10 | #10 |
| evaluation atopic | #10 |
| scale tear | #10 |
| punctal occlusion | #10 |
| layer alterations | #10 |
| lower tmh | #10 |
| leupeptin benzamidine | #10 |
| nonallergic conjunctivitis | #10 |
| muc5ac muc16 | #10 |
| conjunctivitis japan | #10 |
| eye clinically | #10 |
| allergic ocular | #10 |
| eye infrared | #10 |
| meibomian gland obstruction | #10 |
| compared eyes | #10 |
| laminin actins | #10 |
| functions dry | #10 |
| sensation ocular | #10 |
| measuring tear | #10 |
| total tear ige | #10 |
| conjunctival edema | #10 |
| staining oral | #10 |
| treatment vkc | #10 |
| visante optical | #10 |
| staining brush | #10 |
| par2 mast | #10 |
| vmr values | #10 |
| cytometry il4 | #10 |
| aged conjunctivitis | #10 |
| improvement tear | #10 |
| humans conjunctival | #10 |
| bengal stainings | #10 |
| humans mucin | #10 |
| chemokines cxc chemokines | #10 |
| shield ulcer | #10 |
| measurement strip | #10 |
| topical cyclosporine patients | #10 |
| central graft | #10 |
| crth2 chemotaxis | #10 |
| incubated il4 | #10 |
| conjunctivitis spring | #10 |
| status conjunctival | #10 |
| patients ulcers | #10 |
| insufficient local | #10 |
| allergic conjunctivitis spring | #10 |
| substance tears | #10 |
| allergic bronchitis | #10 |
| proliferation conjunctival | #10 |
| underwent slit | #10 |
| complain | #10 |
| produced conjunctival | #10 |
| elicited statistically | #11 |
| elasticity treatment | #11 |
| association outpatient | #11 |
| vcam1 tnfalpha | #11 |
| prevalence dry eye | #11 |
| vmr fva | #11 |
| sensation staining | #11 |
| coherence dry | #11 |
| count conjunctivitis | #11 |
| preserved artificial | #11 |
| smart eye camera | #11 |
| higher muc1 | #11 |
| levocabastine hydrochloride | #11 |
| disease edition | #11 |
| methods conjunctival | #11 |
| therapy conjunctivitis | #11 |
| 1 month reduction | #11 |
| genes corneal | #11 |
| vernal | #11 |
| hel hne | #11 |
| weeks papillary | #11 |
| common conjunctival | #11 |
| vkc adolescent | #11 |
| lamp microscope | #11 |
| cooling operation | #11 |
| amniotic membrane patch | #11 |
| landolt visual | #11 |
| initiation tacrolimus | #11 |
| surgery 13 eyes | #11 |
| purpose metaplasia | #11 |
| function ocular | #11 |
| keratitis observed | #11 |
| palpebral bulbar conjunctiva | #11 |
| fibroblasts pathogenesis | #11 |
| drop artificial | #11 |
| tears conjunctival | #11 |
| interleukin4 male | #11 |
| elisa il4 | #11 |
| vkc | #11 |
| matched dry | #11 |
| schirmer1 test | #11 |
| vkc normal | #11 |
| sensation tear | #11 |
| diagnosis allergic | #11 |
| anesthesia strabismus | #11 |
| test tear | #11 |
| patient atopic | #11 |
| antivcaigg | #11 |
| cytometry oligonucleotide | #11 |
| ophthalmic solution | #11 |
| eosinophils prostaglandin | #11 |
| keratoplasty glaucoma | #12 |
| expression 8 genes | #12 |
| ulcers squamous | #12 |
| iop younger | #12 |
| dermatitis tacrolimus | #12 |
| surface diabetic | #12 |
| 1821 subjects | #12 |
| biomarker allergic | #12 |
| specimens eyes | #12 |
| cornea density | #12 |
| leupeptins mast | #12 |
| receptor crth2 | #12 |
| pemirolast potassium | #12 |
| corneal aesthesiometry | #12 |
| findings conjunctival | #12 |
| density muc5ac | #12 |
| damage height | #12 |
| highspeed highresolution | #12 |
| conjunctival injection | #12 |
| corneal shield | #12 |
| fva vmr | #12 |
| fva visual | #12 |
| fluorescein scores | #12 |
| radiography tears | #12 |
| controls antibody titers | #12 |
| ccl11 conjunctiva | #12 |
| mgd controls | #12 |
| levocabastine patients | #12 |
| conventional slit | #12 |
| density acinar | #12 |
| 002 ophthalmic | #12 |
| patients sac | #12 |
| lacrimal punctal | #12 |
| appearance atopic | #12 |
| tears conjunctivitis | #12 |
| immunologic rejection | #12 |
| keratoconjunctivitis patients | #12 |
| iop glucocorticoids humans | #12 |
| severe binocular | #12 |
| eye diagnosed | #12 |
| acids chemokine | #12 |
| extracts pollens | #12 |
| drugs pge2 | #12 |
| 1cu iol | #12 |
| projects tears | #12 |
| supratarsal injection | #12 |
| selected severity | #12 |
| 1cu accommodating | #12 |
| microscopy efficient | #12 |
| 001 specimens | #12 |
| mmhg elevation | #12 |
| coated lactoferrin | #12 |
| inflammation tear | #13 |
| epithelial disease | #13 |
| improvement vital | #13 |
| dry eye examination | #13 |
| papillary samples | #13 |
| symptoms conjunctival | #13 |
| time fluorescein | #13 |
| interferometry tear | #13 |
| called giant | #13 |
| protein conjunctival | #13 |
| sd105 | #13 |
| topical cyclosporine treatment | #13 |
| syndrome reactivation | #13 |
| 5ac ophthalmic | #13 |
| upper tarsal | #13 |
| anterior segment photography | #13 |
| conclusions ocular | #13 |
| cell flare | #13 |
| ulcers corneal | #13 |
| bengal fluorescein | #13 |
| conjunctival oedema | #13 |
| temperature cataract | #13 |
| suspensions tacrolimus | #13 |
| japan keratoconjunctivitis | #13 |
| chemokines stimulation | #13 |
| coherence viscosupplements | #13 |
| treatment allergic conjunctivitis | #13 |
| glaucoma keratoplasty | #13 |
| scraped samples | #13 |
| glaucoma younger | #13 |
| schirmers test values | #13 |
| outcomes 01 | #13 |
| months healed | #13 |
| keratocytes incubated | #13 |
| thirty eyes | #13 |
| tear hel | #13 |
| vmr measurements | #13 |
| objective signs | #13 |
| aged disposable | #13 |
| applied operation | #13 |
| blood levels tacrolimus | #13 |
| corneal complications | #13 |
| remodeling relevant | #13 |
| compared postsurgical | #13 |
| tear functions | #13 |
| week corneal | #13 |
| stability vital | #13 |
| specimens levels | #13 |
| fluorometholone fml | #13 |
| benzamidines blotting | #14 |
| vehicle eye | #14 |
| test rose | #14 |
| conjunctivitis vernal | #14 |
| clinical corneal | #14 |
| pilocarpine effective | #14 |
| epithelial muc5ac | #14 |
| secrete mediators | #14 |
| fluorometholone humans | #14 |
| functions corneal | #14 |
| fibroblast damage | #14 |
| higher allergic | #14 |
| schirmer1 | #14 |
| 14 flare | #14 |
| blinking patients | #14 |
| solutions retrospective | #14 |
| mcfg treatment | #14 |
| bf 01 | #14 |
| flare count | #14 |
| radioimmunoassay tears | #14 |
| cornea endophthalmitis | #14 |
| occlusion dry | #14 |
| conjunctival allergen challenge | #14 |
| factors conjunctivitis | #14 |
| fungi adolescent | #14 |
| conjunctival impression | #14 |
| visits allergic | #14 |
| dry eye controls | #14 |
| clinically allergic | #14 |
| conjunctivitis background | #14 |
| density tear | #14 |
| eyes 002 | #14 |
| conjunctival muc5ac | #14 |
| proliferative lesion | #14 |
| adherence fibroblasts | #15 |
| surface vital | #15 |
| ocular acrylic | #15 |
| analysis par2 | #15 |
| mucous discharge | #15 |
| steroidal cornea | #15 |
| topical 01 | #15 |
| diseases 2020 | #15 |
| ulcer echinocandins | #15 |
| olopatadine 01 | #15 |
| investigated corneal | #15 |
| rtpcr cytometry | #15 |
| damaged fibroblasts | #15 |
| complications mmc | #15 |
| cytology brush | #15 |
| bromobenzenes child | #15 |
| ophthalmology tokyo | #15 |
| evaluation conjunctival | #15 |
| giant papillary | #15 |
| basal tear secretion | #15 |
| corneal recurrence | #15 |
| effects benzalkonium | #15 |
| day bf | #15 |
| expression realtime pcr | #15 |
| monitoring tear | #15 |
| firstline drug | #15 |
| irritation scores | #15 |
| examined existence | #15 |
| occlusion oct | #15 |
| improvement corneal | #15 |
| receptor pgd2 | #15 |
| occlusion rose | #15 |
| ocular surface mucins | #15 |
| patients vernal | #15 |
| tmh values | #15 |
| superior conjunctiva | #15 |
| bilateral conjunctivitis | #15 |
| correlation tear | #15 |
| eye drop treatment | #15 |
| vkc methods | #15 |
| blepharitis conjunctivitis | #15 |
| tranilast anti | #15 |
| improvement subjective symptoms | #15 |
| ocular itching | #15 |
| mmc female follow | #15 |
| agents blepharitis | #15 |
| ige ecp | #15 |
| complications height | #15 |
| measurements tear | #16 |
| fungi odds | #16 |
| hours visit | #16 |
| ari administration | #16 |
| odds ratio remission | #16 |
| controls papillary | #16 |
| patients vernal keratoconjunctivitis | #16 |
| eosinophils receptor | #16 |
| 2 conjunctival | #16 |
| reduction goblet | #16 |
| ige correlation | #16 |
| female goblet | #16 |
| ulcers positive | #16 |
| total clinical scores | #16 |
| alpha ortho | #16 |
| segment photography | #16 |
| treatment eyelid | #16 |
| safety 01 | #16 |
| temperature conjunctiva | #16 |
| assessment conjunctival | #16 |
| dust allergic | #16 |
| objective ocular | #16 |
| lacrimation | #16 |
| inhibitor ari | #17 |
| clearance corneal | #17 |
| conjunctival samples | #17 |
| warmer treatment | #17 |
| 13 females age | #17 |
| agents cedrus | #17 |
| 20 normal patients | #17 |
| meniscometry | #17 |
| staining muc1 | #17 |
| initiation objective | #17 |
| wear soft | #17 |
| expression eotaxin1 | #17 |
| age dry | #17 |
| fibroblasts mcp1 | #17 |
| muc16 mrna | #17 |
| strip meniscometry | #17 |
| ocular allergic inflammation | #17 |
| eyes schirmer | #17 |
| inflammation blotting | #17 |
| corneal sensation | #17 |
| analyzed 005 | #17 |
| evaluation inflammatory | #17 |
| increased goblet cells | #17 |
| signs ded | #17 |
| ceramide gel | #17 |
| fibroblasts damaged | #17 |
| betamethasone induced | #17 |
| drops eyes | #17 |
| sclera trabeculectomy | #17 |
| 30 ige | #18 |
| tear evaporation rate | #18 |
| dibenzazepines dibenzoxepins | #18 |
| tear function | #18 |
| intraoperative 002 | #18 |
| decrease ocular | #18 |
| tnfα inflammatory response | #18 |
| lower eyes | #18 |
| differentiation inflammatory cells | #18 |
| inflammation lenses | #18 |
| associations level | #18 |
| types dry eye | #18 |
| ulcers compared | #18 |
| studies rose | #18 |
| cytology corneal | #18 |
| rantes response | #18 |
| induce corneal | #18 |
| conclusion ocular | #18 |
| test tears | #18 |
| technique glaucoma | #18 |
| higher tears | #18 |
| noncl wearers | #18 |
| groups spt | #18 |
| ocular surface status | #18 |
| male ophthalmic solutions | #18 |
| correlation clinical signs | #18 |
| obstructive dysfunction | #18 |
| fibroblasts giant | #18 |
| trabeculectomy glaucoma | #18 |
| cytology decrease | #18 |
| cd45 inflammatory | #18 |
| concentrations corneal | #18 |
| evaluation tear | #18 |
| bengal sjogren | #18 |
| complete staining | #18 |
| pollen fungi | #18 |
| ulceration subjects | #18 |
| operation applied | #19 |
| staining scores | #19 |
| sma performed | #19 |
| seldi proteinchip | #19 |
| ige tear | #19 |
| vernal keratoconjunctivitis | #19 |
| 3 severe | #19 |
| inflammatory cells patients | #19 |
| limbal allograft | #19 |
| conjunctivitis topical | #19 |
| 1151 years | #19 |
| prospective study eyes | #19 |
| seldi analysis | #19 |
| periostin biomarker | #19 |
| aged ophthalmic | #19 |
| aged cautery | #19 |
| total signs | #19 |
| steroid female | #19 |
| temperature artificial | #19 |
| human conjunctival | #19 |
| eosinophils adhered | #19 |
| mitomycin ophthalmologic | #19 |
| effective tacrolimus | #19 |
| early efficacy | #19 |
| dha pretreatment | #19 |
| measurements visante | #19 |
| subjects underwent | #19 |
| sodium 01 | #19 |
| microscopy scans | #19 |
| beta1 il1beta | #19 |
| evaluated infrared | #19 |
| outpatient attendance | #19 |
| summarized based | #20 |
| surface findings | #20 |
| decreased conjunctival | #20 |
| bilateral agerelated cataract | #20 |
| corneal impression | #20 |
| pollen association | #20 |
| plaques graded | #20 |
| treated 01 | #20 |
| conclusion tacrolimus | #20 |
| allergic female humans | #20 |
| conjunctivitis primary | #20 |
| evaluate noninferiority | #20 |
| 022 pg | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| common ocular disorders | #20 |
| height tmh | #20 |
| proteins tears | #20 |
| cytology upper | #20 |
| conjunctivitis caused | #20 |
| lower dry | #20 |
| symptoms allergic | #20 |
| patients strip | #20 |
| echinocandins eye | #20 |
| ulcers cell | #20 |
| tears corneal | #20 |
| mucin alterations | #20 |
| xerophthalmia adolescent | #20 |
| persistent epithelial defect | #20 |
| improvements ocular | #20 |
| explain pathogenesis | #20 |
| acuity assessment | #21 |
| levels hel | #21 |
| fluorescence postoperative | #21 |
| crth2 expressed | #21 |
| induced topical | #21 |
| cornea clinical | #21 |
| patients concomitant treatment | #21 |
| cultured conjunctiva | #21 |
| reaction tears | #21 |
| ocular symptoms signs | #21 |
| preventing corneal | #21 |
| microscopy patients | #21 |
| symptoms include | #21 |
| eosinophils flow cytometry | #21 |
| lipid oxidative | #21 |
| patients cedar | #21 |
| peripheral blood eosinophils | #21 |
| eye smaller | #21 |
| adhesion fibroblast | #21 |
| radiation thermometer | #21 |
| reduction topical | #21 |
| keratoconjunctivitis atopic | #21 |
| methane nonmethane hydrocarbons | #21 |
| eye control | #21 |
| surface mucin | #21 |
| ige groups | #21 |
| film lipid | #21 |
| conjunctiva role | #21 |
| tears blood | #21 |
| conclusions topical | #21 |
| flare anterior | #22 |
| fluorescein staining | #22 |
| accommodation amplitude | #22 |
| haze photorefractive | #22 |
| muc5ac patients | #22 |
| 005 topical | #22 |
| therapies allergic | #22 |
| types ocular | #22 |
| serum periostin patients | #22 |
| fibroblasts anti | #22 |
| epithelial lipid | #22 |
| eyes nerve | #22 |
| 01 tacrolimus | #22 |
| mgd adult | #22 |
| negative lower | #22 |
| correlation humidity | #22 |
| tear dynamics | #23 |
| diseases diclofenac | #23 |
| disease atopic | #23 |
| prospectively surgery | #23 |
| corneal fluorescein | #23 |
| il4 tnf | #23 |
| function mucin | #23 |
| tests adenovirus | #23 |
| pge2 supernatants | #23 |
| subjects squamous | #23 |
| labeling tears | #23 |
| solution corneal | #23 |
| 5 females | #23 |
| palpebral conjunctiva | #23 |
| lamp examinations | #23 |
| blood concentration tacrolimus | #23 |
| preschool conjunctivitis | #23 |
| cooling applied | #23 |
| patients topical steroids | #23 |
| hrt confocal | #23 |
| 01 severe | #23 |
| score deqs | #23 |
| solution compared | #23 |
| layer interferometry | #23 |
| 215 ± | #23 |
| fungal corneal | #24 |
| control tear | #24 |
| vital staining | #24 |
| 27yearold male patient | #24 |
| tokyo dental | #24 |
| vkc patients | #24 |
| surface tear | #24 |
| ocular allergies | #24 |
| warming device | #24 |
| histamine development | #24 |
| bengal tears | #24 |
| formation allergic | #24 |
| dermatitis improved | #24 |
| patients tacrolimus ointment | #24 |
| layer tear | #24 |
| tarsal conjunctiva | #24 |
| signs serum | #24 |
| edema drug | #24 |
| cell meter | #24 |
| conjunctiva diabetes | #24 |
| samples conjunctival | #24 |
| local allergic reaction | #24 |
| diseases web | #24 |
| interleukin4 oligonucleotide | #24 |
| vcam1 activated | #25 |
| bengal scores | #25 |
| schedule eosinophil | #25 |
| density squamous | #25 |
| level tears | #25 |
| 0001 dry | #25 |
| corneal plaques | #25 |
| antigen conjunctiva | #25 |
| vkc compared | #25 |
| protein rtpcr | #25 |
| superficial cells | #25 |
| rsv rtpcr | #25 |
| staining goblet | #25 |
| slitlamp examinations | #25 |
| rtpcr rsv | #25 |
| dynamics tear | #25 |
| atopic eosinophils humans | #25 |
| eyes epithelial | #25 |
| steroid eye | #25 |
| confocal prospective | #25 |
| patients atopic diseases | #25 |
| conjunctivitis | #26 |
| adhered fibroblasts | #26 |
| conjunctival inflammation | #26 |
| 005 immunoreactive | #26 |
| dmem f12 medium | #26 |
| eyes topical | #26 |
| treatment meibomian | #26 |
| aureus detected | #26 |
| slit lamp examinations | #26 |
| rapid epithelialization | #26 |
| 100 nylon | #26 |
| smallincision cataract surgery | #26 |
| statistical decrease | #26 |
| corneal ulcers | #26 |
| keratoconjunctivitis caused | #26 |
| tbut tear | #26 |
| subjects measuring | #26 |
| correlated corneal | #26 |
| specific ige positivity | #26 |
| acinar unit | #26 |
| diseases ambient | #26 |
| wheal diameter | #26 |
| singletreatment groups | #26 |
| conclusions improvement | #26 |
| damage adhesion | #26 |
| level il4 | #26 |
| solutions corneal | #26 |
| 01 topical | #26 |
| postkeratoplasty glaucoma | #26 |
| lnfs | #26 |
| symptoms itching | #26 |
| actins collagen | #26 |
| human α defensin | #26 |
| factor exacerbation | #27 |
| associations prevalence | #27 |
| oct prospective | #27 |
| 005 symptoms | #27 |
| child cytological | #27 |
| reaction sensation | #27 |
| alpha eosinophils | #27 |
| therapy conjunctiva | #27 |
| density subbasal | #27 |
| prescribed topical | #27 |
| epinastine | #27 |
| conjunctival epithelial | #27 |
| 01 cyclosporine | #27 |
| tear ocular | #27 |
| lymphocytes specimens | #27 |
| eosinophils fibroblasts | #27 |
| cytometry chemotaxis | #27 |
| antibodies brush | #27 |
| interleukin4 polymerase | #27 |
| provide relief | #28 |
| stress atopic | #28 |
| chemotactic activity eosinophils | #28 |
| giant papillae | #28 |
| 4 5ac | #28 |
| ophthalmic | #28 |
| assay eosinophils | #28 |
| il13 il1beta | #28 |
| prevalence allergic diseases | #28 |
| corneal ulceration | #28 |
| 2 iol | #28 |
| assessment tear | #28 |
| severe ocular | #28 |
| conjunctiva dexamethasone | #28 |
| eosinophil adherence | #28 |
| underwent immunohistochemical | #28 |
| corneal vivo | #28 |
| conjunctival epithelial cells | #28 |
| papillae patients | #28 |
| objective scores | #28 |
| diseases proliferative | #28 |
| solutions ophthalmologic | #28 |
| numbers inflammatory | #29 |
| rosebengal | #29 |
| cys treatment | #29 |
| thermography adolescent | #29 |
| flare cell | #29 |
| scores schirmer | #29 |
| disease periostin | #29 |
| aged thermography | #29 |
| inhibited tranilast | #29 |
| eye mask | #29 |
| corneal conjunctival | #29 |
| sac compared | #29 |
| ketotifen fumarate | #29 |
| conjunctiva dose | #29 |
| 5ac mucins | #29 |
| studies conjunctivitis | #29 |
| allergic regulation | #29 |
| performed morphometric | #29 |
| il2r serum | #30 |
| palpebral | #30 |
| inhibitors pollen | #30 |
| effective artificial | #30 |
| tear serum | #30 |
| conjunctiva cells | #30 |
| symptoms accompanying | #30 |
| ocular surface alterations | #30 |
| conjunctivitis humans | #30 |
| atopic diagnostic | #30 |
| tear ige | #30 |
| minutes visit | #30 |
| dermatitis efficacy | #30 |
| syndromes equipment | #30 |
| eye common | #30 |
| expressed crth2 | #30 |
| common adverse reaction | #30 |
| redness eye | #30 |
| infection conjunctival | #30 |
| fibroblasts protease | #30 |
| regrowth observed | #30 |
| conjunctivitis patients | #30 |
| mucins ophthalmic | #30 |
| specificity tears | #30 |
| recruitment day | #30 |
| acuity fva | #31 |
| scores corneal | #31 |
| vegf cultured | #31 |
| epithelial mucins | #31 |
| inflammation atopic | #31 |
| fibroblasts pcr | #31 |
| worse observed | #31 |
| combinations eosinophils | #31 |
| pathogenesis corneal | #31 |
| schirmer scores | #31 |
| ige negative | #31 |
| dermatitis purpose | #31 |
| atopic 10 | #31 |
| neutrophils severity | #31 |
| properties tears | #31 |
| expressed eosinophils | #31 |
| hel levels | #31 |
| levels july | #31 |
| meibomian gland secretion | #31 |
| disease summarized | #31 |
| tear meniscus height | #32 |
| deqs | #32 |
| schirmer test values | #32 |
| reduced steroid | #32 |
| sign scores | #32 |
| conjunctival cells | #32 |
| keratoconjunctivitis | #32 |
| limbus cornea | #32 |
| eye sjögren | #32 |
| signs improved | #32 |
| western blotting effects | #32 |
| diagnosed dry | #32 |
| tgfbeta1 il1beta | #32 |
| expressibility | #32 |
| analysis tears | #32 |
| prostaglandin cell | #32 |
| substantial interrater agreement | #32 |
| ige histamine | #33 |
| film break | #33 |
| muc 1 | #33 |
| numbers quantitative | #33 |
| visante | #33 |
| 4 grades | #33 |
| allergic double | #33 |
| haze score | #33 |
| conclusions confocal | #33 |
| immunoglobulin interferometry | #33 |
| seasonal young | #33 |
| levocabastine | #33 |
| iop induced | #33 |
| signs evaluated | #33 |
| count prostaglandin | #33 |
| atopic skin disease | #33 |
| edema correlated | #33 |
| alpha fibroblasts | #34 |
| conjunctiva cytokines | #34 |
| 10 objective | #34 |
| il1beta tgfbeta1 | #34 |
| bengal staining | #34 |
| eyes corneal | #34 |
| fluorometholone glucocorticoids | #34 |
| clinical signs patients | #34 |
| proteinchip array | #34 |
| treatment mgd | #34 |
| eye 10 | #34 |
| 01 effective | #34 |
| fibroblasts purpose | #34 |
| therapy histamine | #34 |
| intraocular pressure surgery | #34 |
| objective symptoms | #35 |
| eye 20 | #35 |
| adult asthenopia | #35 |
| cyclosporine cys | #35 |
| 6 months conclusion | #35 |
| hypertension tacrolimus | #35 |
| tear stability | #35 |
| interrater reproducibility | #35 |
| virus capsid antigen | #35 |
| mucins prospective | #35 |
| vdt users | #36 |
| severe allergic | #36 |
| humans keratoconjunctivitis | #36 |
| schirmer 1 | #36 |
| measured tear | #36 |
| tear samples | #36 |
| differential dry | #36 |
| eyes acrysof | #36 |
| tear clearance | #36 |
| anterior scleritis | #36 |
| resection 005 | #36 |
| ocular surface inflammation | #36 |
| functional visual acuity | #36 |
| diseases eosinophil | #36 |
| efficacy groups | #36 |
| scleritis episcleritis | #37 |
| wellrecognized risk | #37 |
| contact lens surface | #37 |
| laser flarecell meter | #37 |
| schirmer 1 test | #37 |
| conducted compliance | #37 |
| recurrence corneal | #37 |
| induced iop | #37 |
| 002 mmc | #37 |
| tacrolimus 12 | #37 |
| oct effective | #37 |
| delefilcon | #37 |
| tears tumor | #37 |
| tenon anesthesia | #37 |
| eyelid skin | #37 |
| gland lipid | #38 |
| exhibited correlation | #38 |
| device eye | #38 |
| allergic cromolyn | #38 |
| pemirolast | #38 |
| 002 mitomycin | #38 |
| aged olopatadine | #38 |
| post cataract | #38 |
| cac japanese | #38 |
| phacoemulsification implantation | #38 |
| infiltration corneal | #39 |
| degree 20 | #39 |
| 0001 specimens | #39 |
| response pretreatment | #39 |
| solutions patient | #39 |
| conjunctiva limbus | #39 |
| accommodating intraocular | #39 |
| 005 oct | #39 |
| tests diagnostic accuracy | #39 |
| tears eye | #39 |
| atopic dry | #39 |
| cells conjunctiva | #39 |
| patients dry eye | #39 |
| cyclosporine dry | #39 |
| drops corneal | #40 |
| biomarkers conjunctiva | #40 |
| eye patients | #40 |
| tmh | #40 |
| decreased inflammation | #40 |
| samples eyes | #40 |
| pharmacology clinical efficacy | #40 |
| subjects specimens | #40 |
| endothelial rejection | #40 |
| ulcers control | #40 |
| acid chemokine | #40 |
| eyes superior | #41 |
| stimulate vascular | #41 |
| treated topical | #41 |
| epitheliopathy | #41 |
| pollution severe | #41 |
| conjunctivitis gpc | #41 |
| ecp concentrations | #41 |
| vegf il1beta | #41 |
| homologous visual | #41 |
| il1beta vegf | #41 |
| α pge2 | #41 |
| treatment dry | #41 |
| efficient noninvasive | #42 |
| scans underwent | #42 |
| allergens conjunctivitis | #42 |
| corneal epithelia | #42 |
| day eye | #42 |
| october july | #42 |
| break time | #42 |
| rollable | #43 |
| instability decreased | #43 |
| hydrocarbons data | #43 |
| conjunctival hyperemia | #43 |
| diseases 2017 | #43 |
| limbus corneal | #43 |
| surface years | #43 |
| revised 2010 | #43 |
| meniscus treatment | #43 |
| cytology revealed | #43 |
| eyelid edema | #43 |
| keratolimbal | #43 |
| microscopy central | #43 |
| tacrolimus treatment | #44 |
| il1beta il4 | #44 |
| epithelial defect | #44 |
| patients rhinoconjunctivitis | #44 |
| oct assessment | #44 |
| collagens fibronectin | #44 |
| elasticity patients | #44 |
| tryptase par2 | #44 |
| activated il4 | #44 |
| subjective symptom | #44 |
| cautery female | #44 |
| agents keratoconjunctivitis | #44 |
| eye 0001 | #44 |
| tear meniscus | #44 |
| abovementioned drugs | #44 |
| adult chemotaxis | #45 |
| topical tacrolimus treatment | #45 |
| rose bengal staining | #45 |
| superficial punctate keratitis | #45 |
| elevation iop | #45 |
| surgery uncorrected | #45 |
| metaplasia mucin | #45 |
| graded 3 | #45 |
| fibroblasts expression | #45 |
| formation corneal | #45 |
| japan particulate | #45 |
| micafungin mcfg | #45 |
| recruiting chemokines | #45 |
| 24 seconds | #45 |
| fibroblasts eosinophils | #45 |
| laser microscopy | #45 |
| fourgrade scale | #45 |
| signs score | #45 |
| metaplasia grade | #45 |
| correlation inflammation | #45 |
| body sensation | #45 |
| surface inflammation | #45 |
| bovine enteric | #45 |
| users contact | #45 |
| understanding ocular | #45 |
| case corneal | #45 |
| inflammation ocular surface | #45 |
| status ocular | #46 |
| il13 serum | #46 |
| suspension effective | #46 |
| staining inflammatory | #46 |
| efficacy combined therapy | #46 |
| fluorometholone | #46 |
| tryptases regulation | #46 |
| 17 japanese patients | #46 |
| graticule | #46 |
| conjunctival | #46 |
| efficacy 01 | #46 |
| corneal cells | #46 |
| surface disease | #46 |
| seconds controls | #46 |
| posttreatment findings | #46 |
| staining conjunctival | #46 |
| diameter plant | #47 |
| blood level | #47 |
| visante oct | #47 |
| allergic female histamine | #47 |
| purpose efficacy | #47 |
| positive muc5ac | #47 |
| patients 01 | #47 |
| suspension 4 | #47 |
| rate ocular | #47 |
| ulcer score | #47 |
| complications corneal | #48 |
| dexamethasone anti | #48 |
| stromal nerve | #48 |
| brush cytology specimens | #48 |
| sac patients | #48 |
| muc5ac mrna | #48 |
| implantation acrysof | #48 |
| stimulation chemokine | #48 |
| cyclosporine ophthalmic | #48 |
| eyes month | #48 |
| enhanced benefits | #48 |
| eyelid warming | #48 |
| 1cu | #49 |
| cxc chemokine genes | #49 |
| male tears | #49 |
| trabeculectomy eyes | #49 |
| adult ca125 | #49 |
| ocular signs | #49 |
| tacrolimus female | #49 |
| fibroblasts incubated | #49 |
| keratocytes fibroblasts | #49 |
| visits air | #49 |
| expression crth2 | #49 |
| eosinophils epithelium | #49 |
| concentrations tears | #49 |
| objective findings | #49 |
| measuring corneal | #50 |
| total severity score | #50 |
| trabeculectomy mitomycin | #50 |
| inflammation conjunctiva | #50 |
| schirmers test | #50 |
| decreased tear | #50 |
| test ocular | #50 |
| meniscus height | #50 |
| aged blinking | #50 |
| patient eyes | #50 |
| disposable soft | #50 |
| ulcers purpose | #50 |
| 4 normal controls | #50 |
| dyes fluorophotometry | #50 |
| ocular surface cells | #51 |
| diagnosis dry | #51 |
| cells brush | #51 |
| periostin patients | #51 |
| effects docosahexaenoic acid | #51 |
| crth2 expression | #51 |
| inflammation cataract | #51 |
| reduction score | #51 |
| members japan | #51 |
| lenses scls | #51 |
| markers atopic | #51 |
| scls | #51 |
| severity objective | #52 |
| examination parameters | #52 |
| tears tomography | #52 |
| eye normal | #52 |
| month initiation | #52 |
| atopic groups | #52 |
| stability corneal | #52 |
| inflammation decline | #52 |
| pcr tgf | #52 |
| biomarker diseases | #52 |
| reaction vehicle | #52 |
| eyelid margins | #52 |
| differential eosinophil | #53 |
| acuity values | #53 |
| stromal nerves | #53 |
| bromfenac | #53 |
| chloride bak | #54 |
| scores tear | #54 |
| suspension treatment | #54 |
| lacrimal glands | #54 |
| presence rsv | #54 |
| oxidation adolescent | #54 |
| 005 month | #54 |
| limbic keratoconjunctivitis | #54 |
| vegf protein secretion | #54 |
| obstructive mgd | #54 |
| combinedtreatment | #55 |
| adult conjunctivitis | #55 |
| epithelial cells expression | #55 |
| conjunctiva drug | #55 |
| antagonists allergic | #55 |
| aged pollen | #55 |
| ocular signs symptoms | #55 |
| local cytokine production | #55 |
| surface clinical | #55 |
| atopic enterotoxins | #55 |
| specular microscopic | #56 |
| topical adolescent | #56 |
| mucin layer | #56 |
| dysfunction atopic | #56 |
| cornea cyclooxygenase | #56 |
| atopic patients | #56 |
| solution placebo | #56 |
| mucin2 mucin4 | #56 |
| allergies adolescent | #56 |
| plant pollens | #56 |
| eosinophil cationic | #56 |
| 3 dry | #56 |
| mechanism giant | #56 |
| film ocular | #56 |
| pain photophobia | #56 |
| ded adult | #56 |
| penetrating limbus | #57 |
| inflammation pge2 | #57 |
| humans interleukin4 | #57 |
| chemotactic responses | #57 |
| accommodating iol | #57 |
| insensible administration | #57 |
| giant papillary conjunctivitis | #57 |
| alpha defensins | #58 |
| seventyeight eyes | #58 |
| drop treatment | #58 |
| papilla formation | #58 |
| schiff staining | #58 |
| staining tear | #58 |
| maximum blood concentration | #58 |
| objective sign | #58 |
| pm25 prevalence | #59 |
| tear instability | #59 |
| intraoperative mitomycin | #59 |
| findings criteria | #59 |
| disease eyes | #59 |
| type allergic | #59 |
| pcr severe | #60 |
| tacrolimus ointment treatment | #60 |
| signs severe | #60 |
| syndromes female | #60 |
| mmc 2 | #60 |
| daily disposable | #60 |
| compared 0001 | #60 |
| diabetic corneal | #60 |
| release inhibitor | #60 |
| evaluation items | #60 |
| nonsteroidal blotting | #61 |
| thermography adult | #61 |
| correlation patients | #61 |
| punctal | #61 |
| allergen mediated | #62 |
| total clinical | #62 |
| values tended | #62 |
| specimens histopathologic | #62 |
| combination epithelium | #62 |
| eotaxin1 expression | #62 |
| amplitude accommodation | #62 |
| eyes 16 | #62 |
| prostaglandin patients | #62 |
| expression eyes | #62 |
| oral pilocarpine | #63 |
| chamber body | #63 |
| conjunctiva patients | #63 |
| il4 role | #63 |
| patient corneal | #63 |
| micafungin treatment | #63 |
| corneal erosion | #63 |
| sac age | #63 |
| hypersensitivity japan | #63 |
| ulcer endophthalmitis | #63 |
| corneal stem | #63 |
| il4 culture | #64 |
| eye adolescent | #64 |
| factor allergic | #64 |
| evaluation corneal | #64 |
| cornea dry | #64 |
| dexamethasone production | #64 |
| positive mucin | #64 |
| radioimmunoassay respiratory | #64 |
| density inflammatory | #64 |
| dust house | #65 |
| tears biomarkers | #65 |
| conclusions corneal | #65 |
| mucins rna | #65 |
| viral radioimmunoassay | #65 |
| microscope methods | #65 |
| live rsv | #65 |
| layer speed | #66 |
| treatment immunosuppressive agents | #66 |
| cases atopic | #66 |
| surface epithelial | #66 |
| diagnosis therapies | #66 |
| cyclosporine eye | #67 |
| period oral | #67 |
| 003 treatment | #67 |
| persistent epithelial | #67 |
| agents keratoplasty | #67 |
| female fluorophotometry | #67 |
| effects 01 | #67 |
| ointment treatment | #68 |
| housedust | #68 |
| time vital | #68 |
| eye dry | #68 |
| counter drugs | #69 |
| glaucoma graft | #69 |
| patients eosinophils | #69 |
| aged tears | #69 |
| occlusion 005 | #69 |
| fibroblasts examined | #69 |
| ophthalmic solutions | #69 |
| fibroblasts corneal | #69 |
| values rose | #70 |
| 1436 patients | #70 |
| crth2 receptor | #70 |
| visit 4 | #70 |
| rhinoconjunctivitis allergic | #70 |
| crth2 pgd2 | #70 |
| 22 eyes | #70 |
| schirmer test | #70 |
| lenses dry | #71 |
| drops treatment | #71 |
| factors tears | #71 |
| allergic dermatitis | #71 |
| dust 20 | #71 |
| glaucoma trabeculectomy | #72 |
| 16 eyes | #72 |
| bulbar conjunctiva | #72 |
| ige eosinophil | #72 |
| tear production | #72 |
| antiallergic agent | #73 |
| punctate keratopathy | #73 |
| immunosuppressive treatment patients | #73 |
| liquid conjunctiva | #73 |
| epithelial structure | #73 |
| pollution prevalence | #73 |
| extraction conjunctiva | #73 |
| fml | #73 |
| surface mucins | #73 |
| fluorophotometry humans | #73 |
| pyridines pyrimidinones | #73 |
| iol acrysof | #74 |
| inflammatory cell numbers | #74 |
| tacrolimus patients | #74 |
| mcfg | #74 |
| eosinophils expressed | #74 |
| agents intraocular | #74 |
| evaluation dry | #74 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| pilocarpine prospective | #75 |
| completely controlled | #75 |
| laser flare | #75 |
| improved infrared | #75 |
| 1 month baseline | #75 |
| dust epidemiologic | #75 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| agents interleukin4 | #76 |
| ccchemokine | #76 |
| surgery technique | #77 |
| capilia | #77 |
| chemical mediator | #77 |
| signs treatment | #77 |
| lower tear | #77 |
| vegf tgfbeta1 | #77 |
| cornea module | #77 |
| slight elongation | #77 |
| excision recurrence | #77 |
| studies suspensions | #77 |
| cytology samples | #77 |
| cytokines stimulate | #77 |
| ophthalmological elasticity | #77 |
| signs observed | #78 |
| pollen compared | #78 |
| concentration il2 | #78 |
| severity ocular | #78 |
| concomitant tacrolimus | #78 |
| drops 1 | #78 |
| japanese guideline | #78 |
| injection reduction | #79 |
| allergic environmental | #79 |
| inhibitors leupeptin | #79 |
| type allergy | #79 |
| dry eye | #79 |
| effects corneal | #79 |
| ocular pain | #79 |
| glaucoma penetrating | #79 |
| extended wear | #79 |
| permeability cornea | #79 |
| il4 ige | #79 |
| mediated par2 | #80 |
| assay epithelial | #80 |
| mgd patients | #80 |
| questionnaires tears | #80 |
| medications required | #80 |
| decreased dry | #81 |
| vegf concentration | #81 |
| antigens histamine | #81 |
| cytology performed | #82 |
| patients conjunctivitis | #82 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| prostaglandin reverse | #82 |
| acrysof iol | #82 |
| data tacrolimus | #83 |
| complications lenses | #83 |
| dental college | #83 |
| tear lipid | #83 |
| patients staphylococcus aureus | #83 |
| expression corneal | #83 |
| papillae | #84 |
| correlation corneal | #84 |
| earlier published data | #84 |
| schirmer | #84 |
| epithelium ocular | #84 |
| cytokines vegf | #84 |
| human reverse | #85 |
| hyperemia induced | #85 |
| patients dry | #85 |
| scleritis patients | #85 |
| inhibitors tryptases | #85 |
| temperature patients | #85 |
| 18 pg | #85 |
| alterations basal | #85 |
| combined penetrating | #85 |
| 5 grades | #85 |
| treatment odds ratio | #85 |
| sligkv | #86 |
| discharge evaluated | #86 |
| daily outpatient | #86 |
| patients eyelid | #86 |
| acuity accommodation | #86 |
| 284 years | #86 |
| inflammation eye | #86 |
| edema scores | #86 |
| pharmacologic intervention | #86 |
| detection limit assay | #87 |
| tacrolimus reduced | #87 |
| confocal ophthalmic | #87 |
| tacrolimus young | #87 |
| regulation muc5ac | #88 |
| daily weather conditions | #88 |
| sclera surgical | #88 |
| tears | #88 |
| post keratoplasty | #88 |
| disease conjunctiva | #88 |
| cells keratocytes | #88 |
| assessment dry | #89 |
| eyes 30 | #89 |
| findings severe | #89 |
| tryptase inhibitors | #89 |
| seasonal perennial | #89 |
| tears visual | #89 |
| tears adult | #90 |
| temperature cornea | #90 |
| glands microscopy | #90 |
| decrease corneal | #90 |
| early ocular | #90 |
| months signs | #90 |
| lower corneal | #90 |
| dressings chronic | #90 |
| cytocentrifuge preparations | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| eye corneal | #92 |
| exposure japan | #92 |
| procedures phacoemulsification | #92 |
| laser cell | #92 |
| techniques trabeculectomy | #92 |
| 7 visit | #93 |
| 005 complications | #93 |
| drug fibroblasts | #93 |
| tears administration | #93 |
| patients correlation | #93 |
| eye cataract surgery | #93 |
| regulation muc1 | #93 |
| stromal corneal | #93 |
| preschool conjunctiva | #93 |
| treatment noninfectious | #93 |
| solutions tears | #93 |
| conjunctival specimens | #93 |
| pgd2 crth2 | #94 |
| exposure exhaust | #94 |
| classification pathogenesis | #94 |
| pollution weather | #94 |
| reaction physical | #94 |
| case allergic | #94 |
| eosinophils patients | #95 |
| relevant factor | #95 |
| induced pgd2 | #95 |
| eye higher | #95 |
| studies tears | #95 |
| twentyeight eyes | #95 |
| score objective | #96 |
| study cyclosporine | #96 |
| staining fluorescein | #96 |
| protein eosinophilia | #96 |
| higher eyes | #96 |
| 128 eyes | #96 |
| cells hel | #97 |
| treatment ecp | #97 |
| 1month treatment | #97 |
| production pge2 | #97 |
| 4 alterations | #97 |
| eyes study | #98 |
| meniscus patients | #98 |
| eyes positive | #98 |
| vdts | #98 |
| staining schirmer | #98 |
| eye tear | #98 |
| equivalent 4 | #99 |
| japan post | #99 |
| 005 recurrence | #99 |
| pseudophakic patients | #99 |
| surgery 6 months | #99 |
| management ocular | #99 |
| cytology evaluation | #99 |
| solution improved | #99 |
| allergic atopic | #100 |
| ointments tacrolimus | #100 |
| conjunctiva corneal | #100 |
| corneal abnormalities | #100 |
| confocal scanning | #100 |
| cells severity | #100 |
| postoperatively statistically | #100 |
| ulcer patient | #100 |
| local pattern | #100 |
| terminals contact | #100 |
| fibroblasts 2 | #101 |
| pathogenesis atopic | #101 |
| eyes 10 | #101 |
| therapy conjunctival | #102 |
| disease classified | #102 |
| effects tranilast | #102 |
| keratolimbal allograft | #102 |
| pathogenesis allergic | #102 |
| severe atopic | #102 |
| agents conjunctivitis | #102 |
| subjective comfort | #103 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| prevalence dry | #103 |
| washing solution | #103 |
| differences ocular | #104 |
| groups dry | #104 |
| syndrome epstein | #104 |
| tears young | #104 |
| topical cyclosporine | #104 |
| allergic cytokines | #104 |
| topic premedication | #104 |
| events scores | #104 |
| values vital | #104 |
| patients bf | #104 |
| aged amnion | #105 |
| inflammation diagnosis | #105 |
| conjunctival impression cytology | #105 |
| baseline initiation | #105 |
| child conjunctival | #105 |
| wearing contact | #105 |
| role staphylococcal | #105 |
| adhesion fibroblasts | #106 |
| pressure keratoplasty | #106 |
| microscopy evaluation | #106 |
| parameters ocular | #106 |
| 14 eyes | #106 |
| conjunctiva cornea | #106 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| eotaxin1 | #107 |
| superficial punctate | #107 |
| topical tacrolimus | #108 |
| resins aged | #108 |
| levels radioimmunoassay | #108 |
| lipid layer | #108 |
| conjunctiva | #108 |
| scores symptoms | #108 |
| film instability | #108 |
| acuity acrylic | #108 |
| induces chemotaxis | #108 |
| dry mouth symptoms | #108 |
| 4 dry | #109 |
| effects dha | #109 |
| tear evaporation | #109 |
| corneal inflammatory | #109 |
| asian dust | #109 |
| il4 human | #109 |
| level tacrolimus | #109 |
| lacrimal salivary | #110 |
| eyes 9 | #110 |
| controls inflammatory | #110 |
| increased evaporation | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| dysfunction mgd | #110 |
| japanese guidelines | #110 |
| severity markers | #111 |
| topical instillation | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| pcr rsv | #113 |
| dibenzoxepins | #113 |
| strabismus surgery | #113 |
| papillary conjunctivitis | #113 |
| anterior segment inflammation | #113 |
| solutions platelet | #113 |
| eye irritation | #114 |
| layer patients | #114 |
| diagnosed allergic | #114 |
| grading scores | #114 |
| incision cataract | #114 |
| lesions atopic | #114 |
| 13 eyes | #115 |
| goblet cell density | #115 |
| male mucin | #115 |
| findings severity | #115 |
| seconds 0001 | #115 |
| allergic eye | #115 |
| sjögrens syndrome patients | #115 |
| conjunctival cell | #115 |
| cholinergic treatment | #115 |
| edition revised | #116 |
| selective histamine | #116 |
| patients seasonal | #117 |
| cooling increased | #117 |
| asia dust | #117 |
| ophthalmology prevalence | #117 |
| metaplasia mucins | #117 |
| samples stained | #117 |
| viscosupplements aged | #117 |
| molecule1 interleukin4 | #118 |
| immunologic receptors prostaglandin | #118 |
| effects docosahexaenoic | #118 |
| generation pge2 | #118 |
| sag genes | #118 |
| skin elasticity | #119 |
| week 005 | #119 |
| 39 mmhg | #119 |
| chemotaxis induced | #119 |
| acuity distance | #119 |
| revealed higher | #119 |
| topical steroids | #119 |
| iop observed | #119 |
| syndromes epithelium | #120 |
| matter prevalence | #120 |
| mitomycin ophthalmic | #121 |
| levels histamine | #121 |
| mitomycinc mmc | #121 |
| soft lenses | #121 |
| distance corrected | #121 |
| chronic allergic | #122 |
| collagen conjunctiva | #123 |
| male ointments | #123 |
| adult conjunctiva | #123 |
| titers ebv | #123 |
| artificial tear | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| month reduced | #126 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| patients atopic | #127 |
| 05ng | #127 |
| subjects vivo | #127 |
| nerves studied | #127 |
| soft contact lenses | #128 |
| gamma increase | #128 |
| 9 genes | #128 |
| combination steroids | #129 |
| elisa levels | #129 |
| acds | #129 |
| fibroblast viability | #129 |
| 361 ± | #129 |
| patients insignificant | #130 |
| functional visual | #130 |
| fva | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| resection severe | #132 |
| eyes fluorescein | #132 |
| management allergic | #132 |
| cataract phacoemulsification | #132 |
| eye drop | #132 |
| 5ac | #132 |
| gene transcription levels | #133 |
| proteins mucin | #133 |
| keratoplasty adult | #133 |
| 19 normal subjects | #133 |
| skin water | #133 |
| treated tacrolimus | #133 |
| normal conjunctival | #134 |
| acrylic iol | #134 |
| density negative | #134 |
| surface examination | #134 |
| pcr hla | #134 |
| solutions phacoemulsification | #135 |
| specimens vivo | #135 |
| stress status | #136 |
| iop treatment | #136 |
| severity 10 | #137 |
| eosinophil adhesion | #137 |
| ophthalmological dry | #137 |
| ocular surface | #137 |
| dry eye patients | #137 |
| antiallergic properties | #137 |
| iol groups | #138 |
| asian dust storms | #138 |
| eosinophil cationic protein | #138 |
| allergic dogs | #139 |
| authors technique | #139 |
| ratio remission | #139 |
| protein ecp | #139 |
| suppressed pretreatment | #140 |
| inflammation prostaglandin | #141 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| findings upper | #142 |
| improvements symptom | #142 |
| interleukin1 interleukin13 | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| 52 mmhg | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| determine central | #144 |
| eye syndromes | #145 |
| symptoms ocular | #145 |
| specimens patient | #145 |
| recordable | #145 |
| fibroblasts alpha | #146 |
| schiff reaction | #146 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| underwent evaluation | #146 |
| virus pathogen | #146 |
| human conjunctiva | #146 |
| eye clinical | #146 |
| 263 years | #147 |
| dscg | #147 |
| impression cytology | #147 |
| hne 4 | #147 |
| diagnosis atopic | #147 |
| required type | #147 |
| increased goblet | #148 |
| 0001 corneal | #148 |
| dynamic visual acuity | #148 |
| ulcer drug | #148 |
| fibroblasts production | #149 |
| japan phenotype | #149 |
| quantitative evaluation | #149 |
| intraocular lens iol | #149 |
| suspension based | #149 |
| cationic protein | #149 |
| patients allergic | #149 |
| concentration tacrolimus | #149 |
| japanese cedar pollen | #150 |
| inflammatory cells | #150 |
| pyrimidinones treatment | #150 |
| inflammation reduction | #151 |
| controls performed | #151 |
| par2 reverse | #152 |
| postoperative secondary | #152 |
| tacrolimus treated | #152 |
| 28 surgery | #153 |
| artificial tears | #153 |
| eyes 11 | #153 |
| induced eotaxin | #153 |
| increased fibroblasts | #153 |
| symptoms objective | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| male mitomycin | #155 |
| inflammation ocular | #155 |
| association pm25 | #156 |
| eyelids female | #156 |
| alcon | #156 |
| chemokine expression | #156 |
| greater inflammation | #157 |
| values improved | #157 |
| rates untreated | #157 |
| ointments skin | #157 |
| pcr increase | #157 |
| lipid infiltration | #157 |
| analysis prostaglandin | #157 |
| inflammatory ocular | #157 |
| japan included | #158 |
| surface status | #158 |
| acuities | #158 |
| trial tacrolimus | #158 |
| immunological characteristics | #159 |
| weeks adverse | #159 |
| 3 boys | #159 |
| study inflammation | #160 |
| acid schiff | #161 |
| mucin 5ac | #161 |
| elevation study | #161 |
| 28 female | #161 |
| muc16 | #161 |
| chemokines production | #161 |
| thirtysix eyes | #161 |
| distance visual acuity | #162 |
| 326 years | #162 |
| surgery topical | #162 |
| bromobenzenes | #162 |
| male meibomian | #162 |
| efficacy tacrolimus | #163 |
| oxidative stress status | #163 |
| olopatadine | #163 |
| visit 7 | #163 |
| studied 21 | #163 |
| il1beta il2 | #163 |
| prevalence ocular | #163 |
| twentynine eyes | #163 |
| 30ng | #164 |
| soft contact | #164 |
| purpose reported | #164 |
| 002 treatment | #164 |
| patients topical | #164 |
| steroid anti | #164 |
| spt positive | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| pgd2 induced | #166 |
| tacrolimus ointment | #167 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| seldi | #169 |
| patients postsurgical | #169 |
| treating refractory | #169 |
| studies tacrolimus | #169 |
| eotaxin chemokine | #169 |
| 12 males | #169 |
| steroidal blotting | #169 |
| local allergic | #169 |
| expression chemokines | #170 |
| status inflammation | #171 |
| conjunctiva conjunctival | #171 |
| management enzyme | #171 |
| subbasal nerve | #172 |
| palisades | #173 |
| fibroblasts fibroblast | #173 |
| distance acuity | #174 |
| subjective symptoms | #174 |
| vivo confocal | #174 |
| slit lamp | #174 |
| pcr flow | #174 |
| standard conventional | #174 |
| status oxidative | #174 |
| 34 eyes | #175 |
| postkeratoplasty | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| aldehydes biomarkers | #177 |
| subbasal | #177 |
| study longterm outcomes | #177 |
| treatment corneal | #177 |
| dust extract | #177 |
| strabismus adolescent | #178 |
| endophthalmitis female | #178 |
| acrysof | #178 |
| reduction intraocular pressure | #178 |
| mild 2 | #178 |
| tryptase | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| dyes follow | #180 |
| migration eosinophils | #180 |
| myopic regression | #180 |
| ceramides child | #180 |
| compared eye | #180 |
| 4 female | #180 |
| japan young adult | #180 |
| cutometer | #181 |
| normal control patients | #181 |
| lipid study | #181 |
| lipoproteins micafungin | #183 |
| serum il4 | #183 |
| blepharitis | #183 |
| male radioallergosorbent | #184 |
| human lymphocyte antigen | #185 |
| igg virus | #185 |
| mucin4 mucins | #185 |
| therapy corneal | #186 |
| nerve prospective | #186 |
| examined parameters | #186 |
| efficacy topical | #187 |
| drug fibroblasts humans | #187 |
| par2 mrna | #187 |
| corneal fibroblasts | #187 |
| suspensions administration | #187 |
| atopic eosinophils | #187 |
| 19 eyes | #188 |
| corneal sensitivity | #188 |
| eye symptoms | #188 |
| il13 increased | #188 |
| allergic cross | #189 |
| seconds patients | #189 |
| sensitivity regulation | #189 |
| production stromal | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| effects diesel | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| improvement subjective | #192 |
| therapeutic study | #193 |
| allergic rhinoconjunctivitis | #193 |
| controls vivo | #193 |
| 26 eyes | #194 |
| fibroblasts inhibited | #195 |
| expression rantes | #195 |
| reactivation epstein | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| methods primary | #197 |
| eyes 21 | #197 |
| treatment topical | #197 |
| 80 allergens | #197 |
| interleukin4 production | #197 |
| tear film stability | #197 |
| elisa performed | #198 |
| combination topical | #198 |
| 28 eyes | #198 |
| tears time | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| photorefractive keratectomy | #201 |
| mcp1 ip10 | #201 |
| perennial allergic | #201 |
| preservative free | #201 |
| pollen allergic | #201 |
| rsv infected | #202 |
| receptor homologous | #202 |
| unit density | #202 |
| hypersensitivity interleukin13 | #202 |
| eosinophils neutrophils | #203 |
| vcam1 icam1 | #204 |
| grade scale | #204 |
| differences iop | #204 |
| ova alum | #204 |
| pge2 human | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| disease dry | #206 |
| eyes cataract | #206 |
| time tbut | #206 |
| disease acd | #206 |
| minutes 8 | #206 |
| ecp levels | #207 |
| glands middle | #207 |
| crth2 | #207 |
| pressure lens | #207 |
| count cornea | #207 |
| formation giant | #207 |
| tears aged | #208 |
| mammalian milk | #208 |
| fluorescein fluorescent | #208 |
| size contact | #208 |
| uncorrected corrected | #209 |
| analysis pm25 | #209 |
| month reduction | #210 |
| human allergic | #210 |
| treatment allergic | #210 |
| refractory conventional | #211 |
| antiallergic drug | #211 |
| oct diagnosis | #211 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| combination tests | #212 |
| inflammation injection | #212 |
| conjunctiva eye | #213 |
| chamber anti | #213 |
| treated refractory | #213 |
| muc5ac | #214 |
| steroids treatment | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| lens purpose | #218 |
| worse eyes | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| august october | #220 |
| conjunctival biopsy | #220 |
| tranilast | #220 |
| metabolism lysine | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| combined therapy | #222 |
| diseases dry | #222 |
| samples correlated | #222 |
| cells crth2 | #222 |
| twentyfour eyes | #222 |
| level ambient | #222 |
| sensitivity measurements | #224 |
| symptoms short | #224 |
| iop corneal | #224 |
| 26 control subjects | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| corneal clarity | #228 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| itching | #229 |
| followup cases | #229 |
| eye signs | #230 |
| corrected distance | #230 |
| treatment superior | #230 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| activity eosinophils | #231 |
| alpha defensin | #232 |
| events initiation | #232 |
| examined level | #232 |
| scleral flap | #232 |
| dye staining | #233 |
| concomitantly administered | #233 |
| proteinchip | #233 |
| cyclosporine treatment | #233 |
| anti allergic | #233 |
| 791 patients | #233 |
| 644 years | #234 |
| examined production | #235 |
| cultured eosinophils | #235 |
| specimens patients | #236 |
| quantitatively evaluate | #236 |
| corneal disease | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| proliferative lesions | #240 |
| diagnostic abilities | #240 |
| tool quantitative | #240 |
| studied subjects | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cromolyn sodium | #242 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| equivalent 2 | #247 |
| subjects males | #247 |
| eye drops | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| response prostaglandin | #251 |
| labeling intercellular | #251 |
| subjective objective | #252 |
| seasonal allergic | #252 |
| syndrome tears | #252 |
| leukocyte child | #252 |
| males 13 | #252 |
| levels tacrolimus | #253 |
| topical oral | #253 |
| improved vision | #255 |
| muc | #255 |
| corneal female | #255 |
| stability positive | #256 |
| rantes expression | #256 |
| dexamethasone inhibition | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| questionnaire objective | #259 |
| tear | #259 |
| role histamine | #260 |
| month treatment | #260 |
| eyes control | #260 |
| eosinophil infiltration | #260 |
| additional medications | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| severity adverse | #264 |
| 1 month treatment | #264 |
| aged mucin | #264 |
| immunohistochemistry increased | #264 |
| keratoplasty pkp | #265 |
| steroid induced | #265 |
| controls p0001 | #266 |
| eyelid diseases | #266 |
| data weekly | #267 |
| signs blood | #267 |
| microscopy negative | #268 |
| respiratory syncytial virus | #268 |
| treatment atopic | #268 |
| studied production | #268 |
| patients sjögren syndrome | #268 |
| sodium drug | #269 |
| computer terminals | #270 |
| h1 histamine | #270 |
| aged aldehyde | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| 13 males | #273 |
| improved visual acuity | #273 |
| aldose reductase inhibitor | #273 |
| studies stevens | #274 |
| epithelium endothelium | #274 |
| combination eosinophils | #274 |
| concentration quantitative | #274 |
| meibomian gland dysfunction | #275 |
| meibomian gland | #277 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| tbut | #278 |
| individuals pcr | #278 |
| grading score | #278 |
| 13 females | #279 |
| eyes 14 | #279 |
| 0001 diagnosis | #279 |
| bloodaqueous barrier | #279 |
| multifunctional glycoprotein | #280 |
| interleukin il4 | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| cautery | #282 |
| disease purpose | #282 |
| expressed th2 | #282 |
| ige positive | #284 |
| gland dysfunction | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| new antifungal | #294 |
| exponential equation | #294 |
| treatment 01 | #294 |
| single therapy | #295 |
| serum periostin | #295 |
| levels ige | #295 |
| hyperemia | #297 |
| surgery statistically | #297 |
| seventy eyes | #299 |
| severity diagnosis | #300 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| moderate 3 | #303 |
| assessed based | #303 |
| cobblestone | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| operation patient | #305 |
| initiation treatment | #305 |
| scores worse | #305 |
| piperidines treatment | #306 |
| eczema severity | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| interleukin13 interleukin2 | #309 |
| evaluation groups | #309 |
| 10 normal subjects | #309 |
| comfort level | #310 |
| compared simple | #310 |
| inflammatory cell | #310 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| regard age | #311 |
| 12 eyes | #311 |
| cytology specimens | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| cells cornea | #317 |
| interferometry light | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| prospective singlearm study | #320 |
| fluorophotometry | #320 |
| dermatitis clinical | #320 |
| il8 rantes | #321 |
| cells chemotaxis | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| agreement weighted | #324 |
| pollen allergen | #324 |
| eyes 19 | #325 |
| 15 30 minutes | #325 |
| 095 ± | #326 |
| icam1 vcam1 expression | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| pressure ocular | #331 |
| treatment 2 weeks | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| cornea diagnostic | #335 |
| values daily | #335 |
| eye treated | #335 |
| proprietary | #336 |
| 27 eyes | #337 |
| corneal epithelial | #337 |
| male staphylococcal | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| corneal infection | #347 |
| measurements treatment | #347 |
| eyes 13 | #348 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| test values | #350 |
| surgery eye | #350 |
| surface diseases | #352 |
| contrast visual | #352 |
| iop elevation | #353 |
| expression allergic | #354 |
| weekly average | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| tear film | #357 |
| patients allergy | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| aureus patients | #363 |
| messenger blotting | #363 |
| injections lidocaine | #364 |
| studies sclera | #368 |
| function laser | #368 |
| plant pollen | #368 |
| treatment ocular | #368 |
| corneae male | #369 |
| mucin1 mucin2 | #370 |
| eyes 17 | #370 |
| postoperative adhesion | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| periodic acid schiff | #374 |
| micafungin middle | #374 |
| cornea female | #375 |
| improvement local | #375 |
| assessment severe | #375 |
| retina tomograph | #376 |
| extraction cell | #376 |
| 10 normal | #377 |
| 4 lower | #377 |
| higher human | #377 |
| phacoemulsification prospective | #377 |
| levels atopic | #377 |
| treatment eyes | #378 |
| tarsal | #378 |
| count child | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| inflammation epithelial | #383 |
| pollinosis | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| limit assay | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| surface alterations | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| sde | #390 |
| severity incidence | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| applied 5 | #395 |
| chronic ocular | #395 |
| techniques interleukin4 | #396 |
| relative percentages | #396 |
| opacity corneal | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| vogt | #404 |
| cells allergic | #404 |
| measurements oct | #404 |
| weather air | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| improved diagnosis | #407 |
| 137 years | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| eyes 15 | #412 |
| specific total | #412 |
| confocal | #412 |
| acids fibroblasts | #412 |
| allergic reaction | #413 |
| counts 1 | #413 |
| 3 months treatment | #413 |
| keratocytes | #414 |
| postoperative inflammation | #416 |
| limbal | #416 |
| penetrating keratoplasty | #418 |
| central cornea | #418 |
| mucin4 | #419 |
| patients comfort | #419 |
| speed resolution | #419 |
| chemokine ccl11 | #419 |
| ophthalmologist | #420 |
| sjögren syndrome | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| 40 minutes | #425 |
| clinical observation | #425 |
| trabeculectomy visual | #430 |
| production 4 | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| 5 women | #438 |
| regulation eye | #438 |
| methods eye | #438 |
| commercial tests | #439 |
| interleukin4 il4 | #440 |
| foldable | #440 |
| subjects studied | #440 |
| vmr | #441 |
| regulation chemokine | #441 |
| fluorescein dye | #441 |
| landolt | #441 |
| anti vcam1 | #442 |
| females normal | #442 |
| adult aldehydes | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| antagonists sedating | #453 |
| versus vehicle | #453 |
| ketotifen | #453 |
| vivo confocal microscopy | #454 |
| normal patients | #454 |
| response allergens | #454 |
| surface disorder | #454 |
| production clearance | #455 |
| 8 genes | #455 |
| water evaporation | #455 |
| ophthalmic nerve | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| amnion cell | #457 |
| normal controls patients | #457 |
| outpatient visits | #457 |
| ocular risk | #457 |
| checker | #459 |
| oct study | #460 |
| distance visual | #461 |
| greatest improvements | #461 |
| keratoplasty penetrating | #462 |
| test evaluation | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| allergy adult | #473 |
| markers severity | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| pollen seasons | #478 |
| fibroblasts primary | #478 |
| 13 mmhg | #478 |
| reduce clinical | #480 |
| newly formed vessels | #480 |
| height measurement | #480 |
| subjects eyes | #481 |
| interleukin 13 | #482 |
| examined prospective | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| acuity intraocular | #495 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| months eyes | #498 |
| corneal | #498 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| stain positive | #499 |
| lens iol | #500 |
| silicone hydrogel | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| studies status | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| eye position | #505 |
| 2 daily | #505 |
| inflammatory status | #506 |
| airborne particulate matter | #506 |
| correlate severity | #506 |
| penetrating male | #507 |
| aldose reductase | #509 |
| induced ocular | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| observed baseline | #519 |
| inhibition production | #519 |
| male water | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| infection rsv | #524 |
| 10 normal volunteers | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| trabeculectomy | #527 |
| studies cornea | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| itchy | #531 |
| rhodanine | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| sac | #539 |
| dependent migration | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| 80 anterior | #541 |
| visit 6 | #541 |
| administration topical | #542 |
| cases flow | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| production cultured | #546 |
| ebv nuclear antigen | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| prospective comparative study | #550 |
| film layer | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| fibroblasts response | #555 |
| disease ded | #555 |
| genechip | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| density assessed | #558 |
| transplantation combined | #558 |
| methods thirty | #559 |
| diesel exhaust particles | #559 |
| ocular infections | #560 |
| eyes iop | #560 |
| differentiation inflammatory | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| iop eyes | #580 |
| 4 mrna | #580 |
| fibrosis fluorescent | #582 |
| apparatus male | #582 |
| lesions normal | #582 |
| department ophthalmology | #584 |
| tnfalpha stimulation | #584 |
| increase vegf | #584 |
| symptoms scores | #588 |
| female humans allergic | #589 |
| patients csa | #589 |
| induced 4 | #589 |
| hladr antigen | #589 |
| corneal epithelium | #589 |
| intraocular male | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| topical adult | #609 |
| inflammation status | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| patients complained | #615 |
| antagonists humans | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| ocular allergy | #617 |
| grades 0 | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| years studied | #625 |
| glaucoma medications | #625 |
| lamp examination | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| redness | #636 |
| corneal haze | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| eosinophils | #639 |
| contact lenses | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| performed modified | #643 |
| months 01 | #643 |
| symptoms signs | #643 |
| observed follow | #644 |
| mellitus double | #645 |
| fibrosis actins | #645 |
| patients healthy volunteers | #650 |
| 2 females | #651 |
| expression administration | #651 |
| viscosupplements | #651 |
| eosinophils flow | #654 |
| analysis existence | #654 |
| diseases methods | #656 |
| comfortable | #657 |
| lacrimal | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| viruses acute | #669 |
| 10 age | #669 |
| damage scores | #669 |
| stimulation rna | #672 |
| cedar | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| objective assessments | #700 |
| levels detection | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| 5 eyes | #718 |
| key cells | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| followup treatment | #730 |
| 11 male | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| reductase inhibitor | #737 |
| symptoms 5 | #737 |
| intraocular lens | #740 |
| density compared | #741 |
| keratectomy | #741 |
| expression real | #744 |
| blood eosinophils | #746 |
| definition classification | #746 |
| unpaired test | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| follow cases | #759 |
| iol implantation | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| intraocular lens implantation | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| pathogenesis severe | #769 |
| oligopeptides rna | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| limbus corneae | #784 |
| fluorescein fluoresceins | #784 |
| blinking | #785 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| lenses intraocular | #792 |
| eyes normal | #792 |
| tacrolimus | #793 |
| increased epithelial | #793 |
| techniques laminin | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| mucin | #813 |
| receptors ccr3 | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| interleukin4 | #821 |
| cells eosinophils | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| preoperative level | #834 |
| lymphocytes compared | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| patients operation | #841 |
| individuals patients | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| new surgical technique | #845 |
| elevated iop | #845 |
| 2 weeks treatment | #848 |
| levels air | #848 |
| exhaust | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| purpose prospectively | #855 |
| cell area | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| histamine h1 | #865 |
| thiazolidines | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| benzamidine | #880 |
| h1 antagonists | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| bleb | #887 |
| patients condition | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| treatment symptoms | #928 |
| 8 males | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| epithelialization | #937 |
| beta1 tumor | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| humans muscarinic | #946 |
| factor production | #946 |
| wheal | #947 |
| mgd | #949 |
| radioallergosorbent test | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| 3 eyes | #959 |
| aldose | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| sedating | #961 |
| intracellular infection | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| tenon | #994 |
| observed conclusions | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| methods sixteen | #1002 |
| observed vivo | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| eye infections | #1012 |
| time year | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| blink | #1017 |
| 1 2 weeks | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| cells fibroblasts | #1044 |
| lysine 4 | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| disposable | #1067 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| syncytial virus | #1080 |
| ade | #1080 |
| expression icam1 | #1082 |
| allergic inflammatory | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| lens capsule | #1116 |
| rose | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| cultures human | #1133 |
| assay fibroblasts | #1133 |
| clinical findings | #1133 |
| treatment objective | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| 4 daily | #1146 |
| p0035 | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| fibronectins fibrosis | #1189 |
| ophthalmological female | #1189 |
| immune mechanisms | #1189 |
| levels chemokines | #1191 |
| adult dermatitis | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| concentrations alpha | #1210 |
| 84 ± | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| higher severe | #1316 |
| chemokines chemotaxis | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| 830 | #1322 |
| ccl11 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| 18 eyes | #1399 |
| female glucocorticoids | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| detected frequently | #1499 |
| western cells | #1499 |
| male metaplasia | #1500 |
| bulbar | #1502 |
| studies suture | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| ortho aminobenzoates | #1602 |
| preservative | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| disease defined | #1713 |
| outcome visual | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| japan methods | #1823 |
| receptor par2 | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 5 minutes | #1970 |
| 9 males | #1970 |
| 4 males | #1971 |
| device treatment | #1972 |
| comfort | #1972 |
| gpc | #1974 |
| corrected visual | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| coherence treatment | #2038 |
| treated eyes | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| vital | #2246 |
| rater agreement | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| groups difference | #2250 |
| allergic seasonal | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| topical treatment | #2312 |
| clinical appearance | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| fungal female | #2498 |
| enteric coated | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| total ige | #2772 |
| matched normal | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| higher cases | #2821 |
| atopic dermatitis | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| test performed | #2907 |
| anterior chamber | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| helper type | #3773 |
| management disease | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| thirtysix patients | #5224 |
| epithelium | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| rejection humans | #6543 |
| house dust | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| alkylating | #18391 |
| stained | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Kjør rapport | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Kjent for Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Kjent for Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Kjent for Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Kjent for Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Kjent for Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Kjent for Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Kjent for Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Kjent for Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Kjent for Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Kjent for Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Kjent for Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Kjent for Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Kjent for Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Kjent for Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Nøkkelpersoner for Allergic Conjunctivitis
Toppkols i verden
Hiroshi Fujishima:Ekspertvirkning
Konsepter somHiroshi Fujishimahar direkte innflytelse:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:Kol Impact
Konsepter relatert til arbeidet til andre forfattere somfor which Hiroshi Fujishima har innflytelse:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Er dette profilen din? Krev profilen din Kopier url Legg inn lenke til profilen din |